@NP	this day	1191
@NP	no curative treatment	1200
@NP	lost functions	1249
@NP	extensive experimental studies	1276
@NP	recovery	1337
@NP	SCI	1352
@NP	One of the most promising therapies	1357
@NP	One	1357
@NP	the most promising therapies	1364
@NP	the use of olfactory ensheathing cells -LRB- OECs -RRB-	1405
@NP	the use	1405
@NP	olfactory ensheathing cells -LRB- OECs -RRB-	1416
@NP	olfactory ensheathing cells	1416
@NP	OECs	1445
@NP	OECs	1452
@NP	either the olfactory bulbs -LRB- OB-OECs -RRB-	1478
@NP	either the olfactory bulbs	1478
@NP	OB-OECs	1506
@NP	olfactory mucosa	1523
@NP	OM-OECs	1541
@NP	a less invasive approach for autotransplantation	1561
@NP	a less invasive approach	1561
@NP	autotransplantation	1590
@NP	the vast majority of experimental transplantations	1619
@NP	the vast majority	1619
@NP	experimental transplantations	1640
@NP	OB-OECs	1692
@NP	the OM	1709
@NP	a more accessible source of OECs	1727
@NP	a more accessible source	1727
@NP	OECs	1755
@NP	the ability	1774
@NP	OM-OECs	1789
@NP	comparison to OB-OECs to induce spinal cord recovery in the same lesion paradigm	1800
@NP	comparison	1800
@NP	OB-OECs to induce spinal cord recovery in the same lesion paradigm	1814
@NP	spinal cord recovery in the same lesion paradigm	1832
@NP	spinal cord recovery	1832
@NP	the same lesion paradigm	1856
@NP	We	1907
@NP	present data	1915
@NP	a multiparametric approach	1934
@NP	the repair potential of OB-OECs and OM-OECs	2064
@NP	the repair potential	2064
@NP	OB-OECs and OM-OECs	2088
@NP	primary	2120
@NP	cultures	2140
@NP	a severe model of SCI	2155
@NP	a severe model	2155
@NP	SCI	2173
@NP	Our data	2178
@NP	transplantation of OECs obtained from OB or OM	2204
@NP	transplantation	2204
@NP	OECs obtained from OB or OM	2223
@NP	OECs	2223
@NP	OB or OM	2242
@NP	electrophysiological and functional recovery	2259
@NP	astrocyte reactivity and glial scar formation	2313
@NP	astrocyte reactivity	2313
@NP	glial scar formation	2338
@NP	axonal regrowth	2372
@NP	We	2389
@NP	the purification step	2407
@NP	OM-OECs	2446
@NP	OB-OECs	2477
@NP	our study	2498
@NP	transplantation of OECs from OM	2532
@NP	transplantation	2532
@NP	OECs from OM	2551
@NP	OECs	2551
@NP	OM	2561
@NP	the best benefit/risk ratio	2575
@NP	the safety of access of OM	2616
@NP	the safety	2616
@NP	access of OM	2630
@NP	access	2630
@NP	OM	2640
@NP	the results induced by transplantations of OM-OECs	2647
@NP	the results	2647
@NP	transplantations of OM-OECs	2670
@NP	transplantations	2670
@NP	OM-OECs	2690
@NP	purified OM-OECs in addition to induce recovery	2707
@NP	purified OM-OECs	2707
@NP	addition to induce recovery	2727
@NP	recovery	2746
@NP	60 days	2787
@NP	the spinal cord	2800
@NP	our results	2828
@NP	strong support	2848
@NP	these cells as a viable therapy for SCI	2867
@NP	these cells	2867
@NP	a viable therapy for SCI	2882
@NP	a viable therapy	2882
@NP	SCI	2903
@NP	Introduction Spinal cord injury -LRB- SCI -RRB-	2909
@NP	Introduction Spinal cord injury	2909
@NP	Introduction	2909
@NP	Spinal cord injury	2922
@NP	SCI	2942
@NP	a devastating disease leading to a loss of neural conduction	2950
@NP	a devastating disease	2950
@NP	a loss of neural conduction	2983
@NP	a loss	2983
@NP	neural conduction	2993
@NP	Sensory and motor pathways	3012
@NP	paraplegia or tetraplegia	3068
@NP	patients	3098
@NP	SCI	3114
@NP	several mechanisms	3118
@NP	place	3142
@NP	astrocyte reactivity	3156
@NP	formation	3178
@NP	the glial scar	3191
@NP	invasion	3207
@NP	inflammatory cells	3219
@NP	a lack of axonal regrowth	3251
@NP	a lack	3251
@NP	axonal regrowth	3261
@NP	1,2 -RSB-	3278
@NP	this day	3287
@NP	no curative treatment	3296
@NP	clinical use	3335
@NP	extensive experimental studies	3359
@NP	axonal regrowth	3422
@NP	functional recovery	3453
@NP	SCI using various therapies -LSB- 3,4 -RSB-	3479
@NP	SCI	3479
@NP	various therapies -LSB- 3,4 -RSB-	3489
@NP	various therapies	3489
@NP	3,4 -RSB-	3508
@NP	Many of these approaches	3514
@NP	Many	3514
@NP	these approaches	3522
@NP	cellular transplantation	3549
@NP	Schwann cells -LRB- SC -RRB- , neural stem cells	3583
@NP	Schwann cells -LRB- SC -RRB-	3583
@NP	Schwann cells	3583
@NP	SC	3598
@NP	neural stem cells	3603
@NP	pluripotent stem cells or olfactory ensheathing cells	3630
@NP	OECs , `` OECs ''	3685
@NP	all the olfactory ensheathing cells	3716
@NP	contrasting results -LSB- 5	3758
@NP	contrasting results	3758
@NP	5	3779
@NP	12	3781
@NP	OECs	3786
@NP	considerable interest for the past decade due to the fact	3803
@NP	considerable interest	3803
@NP	the past decade due to the fact	3829
@NP	the past decade	3829
@NP	the fact	3852
@NP	OECs	3866
@NP	a great potential	3882
@NP	both functional and anatomical recoveries	3911
@NP	SCI	3959
@NP	13 -RSB-	3964
@NP	OECs	3969
@NP	neural crest cells	3978
@NP	neurogenesis	4018
@NP	the primary olfactory system throughout life	4044
@NP	the primary olfactory system	4044
@NP	life	4084
@NP	mammals -LSB- 14 -RSB-	4092
@NP	mammals	4092
@NP	14 -RSB-	4101
@NP	transplantation in lesioned spinal cord	4116
@NP	transplantation	4116
@NP	lesioned spinal cord	4135
@NP	OECs	4157
@NP	axonal regrowth	4184
@NP	astrocyte reactivity , increase angiogenesis	4210
@NP	astrocyte reactivity	4210
@NP	increase angiogenesis	4232
@NP	glial scar leading	4267
@NP	functional recovery in various models of SCI in rodents -LSB- 15 -- 19 -RSB-	4289
@NP	functional recovery	4289
@NP	various models of SCI in rodents -LSB- 15 -- 19 -RSB-	4312
@NP	various models	4312
@NP	SCI in rodents -LSB- 15 -- 19 -RSB-	4330
@NP	SCI	4330
@NP	rodents -LSB- 15 -- 19 -RSB-	4337
@NP	rodents	4337
@NP	15 -- 19	4346
@NP	OECs	4364
@NP	several subpopulations	4388
@NP	the role of each of them following transplantation in injured spinal cord	4415
@NP	the role	4415
@NP	each of them following transplantation in injured spinal cord	4427
@NP	each	4427
@NP	them	4435
@NP	transplantation in injured spinal cord	4450
@NP	transplantation	4450
@NP	injured spinal cord	4469
@NP	20,21 -RSB-	4512
@NP	OECs	4534
@NP	two different regions	4560
@NP	olfactory mucosa -LRB- OM -RRB- and olfactory bulbs -LRB- OB -RRB-	4583
@NP	olfactory mucosa -LRB- OM -RRB-	4583
@NP	olfactory mucosa	4583
@NP	OM	4601
@NP	olfactory bulbs -LRB- OB -RRB-	4609
@NP	olfactory bulbs	4609
@NP	OB	4626
@NP	it	4634
@NP	OECs obtained from OM -LRB- OM-OECs -RRB- and OB -LRB- OB-OECs -RRB-	4650
@NP	OECs	4650
@NP	OM -LRB- OM-OECs -RRB- and OB -LRB- OB-OECs -RRB-	4669
@NP	OM	4669
@NP	OM-OECs	4673
@NP	OB	4686
@NP	OB-OECs	4690
@NP	the same properties and effects after transplantation in vivo -LSB- 22,23 -RSB-	4708
@NP	the same properties and effects	4708
@NP	transplantation in vivo -LSB- 22,23 -RSB-	4746
@NP	transplantation	4746
@NP	22,23 -RSB-	4771
@NP	culture conditions , in particular the presence of microenvironment ,	4789
@NP	culture conditions	4789
@NP	particular the presence of microenvironment	4812
@NP	particular the presence	4812
@NP	microenvironment	4839
@NP	OECs behaviors in vitro and in vivo	4879
@NP	OECs behaviors	4879
@NP	vivo	4910
@NP	21,24 -RSB-	4916
@NP	OM-OECs	4924
@NP	primary olfactory neurons and fibroblasts	4960
@NP	OB	5011
@NP	OECs	5015
@NP	contact with fibroblasts and astrocytes both in vitro and in vivo -LSB- 25 -- 28	5027
@NP	contact with fibroblasts and astrocytes	5027
@NP	contact	5027
@NP	fibroblasts and astrocytes	5040
@NP	in vitro and in vivo -LSB- 25 -- 28	5072
@NP	in vitro and in vivo -LSB-	5072
@NP	vivo	5088
@NP	25 -- 28	5094
@NP	a clinical purpose	5106
@NP	these two aspects	5125
@NP	some relevant consequences	5148
@NP	clinical use	5188
@NP	OECs	5202
@NP	autotransplantation	5229
@NP	a simple biopsy of OM	5259
@NP	a simple biopsy	5259
@NP	OM	5278
@NP	Rubio et al.	5317
@NP	Rubio	5317
@NP	et al.	5323
@NP	an unilateral bulbectomy	5337
@NP	OB -LSB- 29 -RSB-	5367
@NP	OB	5367
@NP	29 -RSB-	5371
@NP	OECs	5389
@NP	primary cultures	5424
@NP	additional purification steps	5450
@NP	it	5484
@NP	time in culture	5510
@NP	time	5510
@NP	culture	5518
@NP	neurogenic properties of OECs -LSB- 30,31 -RSB-	5536
@NP	neurogenic properties	5536
@NP	OECs -LSB- 30,31 -RSB-	5561
@NP	OECs	5561
@NP	30,31 -RSB-	5567
@NP	we	5580
@NP	the potential	5606
@NP	OECs	5623
@NP	the two sources	5655
@NP	a severe model of SCI	5674
@NP	a severe model	5674
@NP	SCI	5692
@NP	a multiparametric approach	5699
@NP	We	5727
@NP	transplantation of OECs	5747
@NP	transplantation	5747
@NP	OECs	5766
@NP	electrophysiological and functional recovery	5779
@NP	astrocyte reactivity and glial scar formation	5833
@NP	astrocyte reactivity	5833
@NP	glial scar formation	5858
@NP	axonal regrowth	5892
@NP	our model	5922
@NP	transplantation of OECs from OM	5933
@NP	transplantation	5933
@NP	OECs from OM	5952
@NP	OECs	5952
@NP	OM	5962
@NP	the best benefit/risk source	5976
@NP	support for these cells	6016
@NP	support	6016
@NP	these cells	6028
@NP	a new therapy for SCI	6043
@NP	a new therapy	6043
@NP	SCI	6061
@NP	human	6068
@NP	Materials	6076
@NP	Methods General Overview An overview of the paradigms used in this study	6090
@NP	Methods General Overview An overview	6090
@NP	Methods	6090
@NP	General Overview	6098
@NP	An overview	6115
@NP	the paradigms used in this study	6130
@NP	the paradigms	6130
@NP	this study	6152
@NP	Figure 1	6179
@NP	cellular transplantations	6198
@NP	complete transection of the spinal cord	6245
@NP	complete transection	6245
@NP	the spinal cord	6269
@NP	two sources -LRB- OB and OM -RRB-	6290
@NP	two sources	6290
@NP	OB and OM	6303
@NP	OB	6303
@NP	OM	6310
@NP	two different ways -LRB- primary and purified -RRB-	6330
@NP	two different ways	6330
@NP	primary and purified	6350
@NP	OB -LRB- Primary OB -RRB- and OM -LRB- Primary OM -RRB-	6377
@NP	OB	6377
@NP	Primary OB	6381
@NP	OM	6397
@NP	Primary OM	6401
@NP	primary cultures	6414
@NP	5 days in vitro -LRB- DIV -RRB-	6455
@NP	5 days	6455
@NP	vitro	6465
@NP	DIV	6472
@NP	OB -LRB- Purified OB -RRB-	6482
@NP	OB	6482
@NP	OB	6495
@NP	purified cultures	6500
@NP	10 DIV	6542
@NP	OM -LRB- Purified OM -RRB-	6554
@NP	OM	6554
@NP	OM	6567
@NP	purified cultures	6572
@NP	14 DIV	6614
@NP	All different cell types	6622
@NP	spinal cord transection	6683
@NP	All groups of animals	6708
@NP	All groups	6708
@NP	animals	6722
@NP	15 , 30 and 60 days after surgery	6744
@NP	15	6744
@NP	30 and 60 days after surgery	6748
@NP	30 and 60 days	6748
@NP	surgery	6769
@NP	electrophysiological and locomotor activities	6781
@NP	Histological analyses	6828
@NP	60 days	6873
@NP	transplantation	6887
@NP	all the groups	6907
@NP	additional animals	6929
@NP	Md , Primary OB	6961
@NP	Md	6961
@NP	Primary OB	6965
@NP	OM	6989
@NP	higher potential to promote recovery	7006
@NP	higher potential	7006
@NP	recovery	7034
@NP	MRI analyses	7058
@NP	7 days	7071
@NP	transplantation	7084
@NP	OM purified cells , which constituted the most relevant group for clinical use ,	7110
@NP	OM	7110
@NP	cells	7122
@NP	the most relevant group for clinical use	7147
@NP	the most relevant group	7147
@NP	clinical use	7175
@NP	GFP	7207
@NP	them	7224
@NP	30 and 60 days after transplantation	7229
@NP	30 and 60 days	7229
@NP	transplantation	7250
@NP	Animals Experiments	7267
@NP	acceptance	7308
@NP	the local Ethics Committee for Animal Experiments in Normandy	7322
@NP	the local Ethics Committee	7322
@NP	Animal Experiments in Normandy	7353
@NP	Animal Experiments	7353
@NP	Normandy	7375
@NP	N/02 - 11-10/22	7385
@NP	N/02	7385
@NP	11-10/22	7391
@NP	11-13 in accordance	7400
@NP	11-13	7400
@NP	accordance	7409
@NP	the French law	7425
@NP	the protection of animals	7443
@NP	the protection	7443
@NP	animals	7461
@NP	this study , 95 8-weeks old and 30 3 -- 4 weeks old male	7474
@NP	this study	7474
@NP	95 8-weeks old	7486
@NP	30 3 -- 4 weeks old male	7505
@NP	30 3	7505
@NP	4 weeks old male	7510
@NP	4 weeks	7510
@NP	inbred Fischer rats	7527
@NP	Charles River	7558
@NP	L'Arbresle , France	7573
@NP	Individual rats	7594
@NP	implantation of glass tag -LRB- Biolog-id , Bernay , France -RRB-	7629
@NP	implantation	7629
@NP	glass tag -LRB- Biolog-id , Bernay , France -RRB-	7645
@NP	glass tag	7645
@NP	Biolog-id	7656
@NP	Bernay	7667
@NP	France	7675
@NP	glass tag numbers	7684
@NP	analyses	7736
@NP	Cell Culture All cultures	7746
@NP	Cell Culture	7746
@NP	All cultures	7759
@NP	semi-sterile conditions	7795
@NP	autoclaved surgery tools	7824
@NP	Primary cultures	7850
@NP	OB and OM primary cultures	7868
@NP	slight modifications -LSB- 25,26 -RSB-	7938
@NP	slight modifications	7938
@NP	25,26 -RSB-	7960
@NP	rats	7977
@NP	isofluorane	8008
@NP	OB from one rat	8038
@NP	OB	8038
@NP	one rat	8046
@NP	1 ml	8095
@NP	Hank 's	8103
@NP	salt solution -LRB- H.B.S.S , Invitrogen , Carlsbad , CA -RRB-	8119
@NP	salt solution	8119
@NP	H.B.S.S	8134
@NP	Invitrogen	8143
@NP	Carlsbad , CA	8155
@NP	the meninges	8185
@NP	H.B.S.S containing 0.1 % trypsin -LRB- Invitrogen -RRB- and OB	8199
@NP	H.B.S.S	8199
@NP	0.1 % trypsin -LRB- Invitrogen -RRB- and OB	8218
@NP	0.1 % trypsin -LRB- Invitrogen -RRB-	8218
@NP	0.1 % trypsin	8218
@NP	Invitrogen	8232
@NP	OB	8248
@NP	45 min at 37 °C	8270
@NP	45 min	8270
@NP	37 °C	8280
@NP	Trypsinization	8286
@NP	Dulbecco 's	8323
@NP	Eagle 's	8343
@NP	Ham 's F12 medium -LRB- D.M.E.M / F12 , Invitrogen -RRB-	8351
@NP	Ham 's F12 medium	8351
@NP	Ham 's	8351
@NP	D.M.E.M	8369
@NP	F12 , Invitrogen	8377
@NP	F12	8377
@NP	Invitrogen	8382
@NP	10 % Fetal Bovine Serum	8413
@NP	F.B.S	8437
@NP	Invitrogen	8444
@NP	1 % penicillin/streptomycin -LRB- Invitrogen -RRB- -LRB- DF-10S -RRB-	8460
@NP	1 % penicillin/streptomycin -LRB- Invitrogen -RRB-	8460
@NP	1 % penicillin/streptomycin	8460
@NP	Invitrogen	8488
@NP	DF-10S	8501
@NP	The tissue	8510
@NP	1.000 RPM for 3 min	8542
@NP	1.000 RPM	8542
@NP	3 min	8556
@NP	DF-10S	8578
@NP	Tissue	8610
@NP	3 ml DF-10S using a micropipette	8640
@NP	3 ml DF-10S	8640
@NP	a micropipette	8658
@NP	a homogenous cell suspension	8680
@NP	undigested tissue blocks	8738
@NP	pipetting	8779
@NP	cells	8796
@NP	1.5 -- 3.106 cells per flask	8815
@NP	1.5	8815
@NP	3.106 cells per flask	8819
@NP	3.106 cells	8819
@NP	flask	8835
@NP	DF-10S in 25 cm2 flasks -LRB- Starlab , Bagneux , France -RRB-	8845
@NP	DF-10S	8845
@NP	25 cm2 flasks -LRB- Starlab , Bagneux , France -RRB-	8855
@NP	25 cm2 flasks	8855
@NP	Starlab	8870
@NP	Bagneux	8879
@NP	France	8888
@NP	poly-L-Lysine -LRB- 50 µg / ml , Invitrogen -RRB-	8913
@NP	poly-L-Lysine	8913
@NP	50 µg	8928
@NP	ml , Invitrogen	8935
@NP	ml	8935
@NP	Invitrogen	8939
@NP	The flasks	8952
@NP	37 °C , 5 % CO2	8981
@NP	37 °C	8981
@NP	5 % CO2	8987
@NP	The medium	8995
@NP	every two days	9018
@NP	Five days	9034
@NP	OB primary cultures	9059
@NP	transplantation	9093
@NP	the same rats	9113
@NP	the nasal cavity	9128
@NP	a spatula	9172
@NP	OM	9186
@NP	small pieces	9200
@NP	Care	9214
@NP	cartilage	9246
@NP	a short rinse in H.B.S.S	9263
@NP	a short rinse	9263
@NP	H.B.S.S	9280
@NP	samples from 1 rat	9289
@NP	samples	9289
@NP	1 rat	9302
@NP	1 ml of collagenase A -LRB- 0.5 % -RRB-	9339
@NP	1 ml	9339
@NP	collagenase A -LRB- 0.5 % -RRB-	9347
@NP	collagenase A	9347
@NP	0.5 %	9362
@NP	45 min at 37 °C -LRB- Roche Diagnostics , Penzbeg , Germany -RRB-	9372
@NP	45 min	9372
@NP	37 °C -LRB- Roche Diagnostics , Penzbeg , Germany -RRB-	9382
@NP	37 °C	9382
@NP	Roche Diagnostics	9388
@NP	Penzbeg	9407
@NP	Germany	9416
@NP	The OM	9425
@NP	the rat	9456
@NP	its posterior position on the nasal septum	9467
@NP	its posterior position	9467
@NP	the nasal septum	9493
@NP	the yellowish appearance of the epithelial surface	9517
@NP	the yellowish appearance	9517
@NP	the epithelial surface	9545
@NP	Care	9569
@NP	the anterior edge	9593
@NP	the OM which could have been contaminated with respiratory epithelium	9614
@NP	the OM	9614
@NP	respiratory epithelium	9661
@NP	Respiratory mucosa	9685
@NP	the dorso-anterior region of the septum	9721
@NP	the dorso-anterior region	9721
@NP	the septum	9750
@NP	samples	9768
@NP	the same protocol that for OB cultures -LSB- 25 -RSB-	9797
@NP	the same protocol	9797
@NP	OB cultures	9824
@NP	25 -RSB-	9837
@NP	Five days	9842
@NP	OM primary cultures	9867
@NP	transplantation	9901
@NP	Olfactory ensheathing cells purification .	9918
@NP	Olfactory ensheathing cells	9918
@NP	purification	9946
@NP	OECs purification from OB	9960
@NP	OECs purification	9960
@NP	OB	9983
@NP	method	10010
@NP	Nash	10030
@NP	the differing rates	10044
@NP	attachment of the various harvested cell types -LSB- 32 -RSB-	10067
@NP	attachment	10067
@NP	the various harvested cell types -LSB- 32 -RSB-	10081
@NP	the various	10081
@NP	cell types -LSB- 32 -RSB-	10103
@NP	cell types	10103
@NP	32 -RSB-	10115
@NP	the method of differential adhesion	10129
@NP	the method	10129
@NP	differential adhesion	10143
@NP	a very low adhesion rate of OEC	10177
@NP	a very low adhesion rate	10177
@NP	OEC	10205
@NP	the surface of uncoated culture flasks -LSB- 32,33 -RSB-	10212
@NP	the surface	10212
@NP	uncoated culture flasks -LSB- 32,33 -RSB-	10227
@NP	uncoated culture flasks	10227
@NP	32,33 -RSB-	10252
@NP	The cell suspension obtained from OB	10260
@NP	The cell suspension	10260
@NP	OB	10294
@NP	DF-10S	10316
@NP	uncoated flask	10334
@NP	37 °C with 5 % CO2	10365
@NP	37 °C	10365
@NP	5 % CO2	10375
@NP	18 h	10389
@NP	the supernatant	10395
@NP	other uncoated flasks	10440
@NP	additional 36 h.	10480
@NP	The supernatants from these flasks	10497
@NP	The supernatants	10497
@NP	these flasks	10519
@NP	25 cm2	10561
@NP	poly-L-lysine-coated culture flasks	10568
@NP	DF-10S	10609
@NP	Ten days	10617
@NP	OB purified cultures	10641
@NP	OB	10641
@NP	cultures	10653
@NP	transplantation	10676
@NP	OECs purification from OM	10693
@NP	OECs purification	10693
@NP	OM	10716
@NP	the method described by Bianco and modified by Gueye et al. -LSB- 34,35 -RSB-	10742
@NP	the method	10742
@NP	Bianco	10766
@NP	Gueye et al. -LSB-	10789
@NP	34,35 -RSB-	10803
@NP	one week in primary culture	10826
@NP	one week	10826
@NP	primary culture	10838
@NP	cells	10855
@NP	trypsinisation	10875
@NP	serum-free culture medium	10906
@NP	25 ng/mL	10950
@NP	growth factor	10975
@NP	a -LRB- Sigma Aldrich , St Louis , MO -RRB-	10989
@NP	Sigma Aldrich	10992
@NP	St Louis	11007
@NP	MO	11017
@NP	pre-coated flasks -LRB- poly-L-Lysine 50 µg/ml -RRB-	11026
@NP	pre-coated flasks	11026
@NP	poly-L-Lysine 50 µg/ml	11045
@NP	poly-L-Lysine	11045
@NP	50 µg/ml	11059
@NP	The second passage	11070
@NP	1 week	11103
@NP	Fourteen days	11117
@NP	OM purified cultures	11146
@NP	OM	11146
@NP	cultures	11158
@NP	transplantation	11181
@NP	Preparation of the cells for grafting .	11198
@NP	Preparation	11198
@NP	the cells for grafting	11213
@NP	the cells	11213
@NP	grafting	11227
@NP	transplantation	11244
@NP	cultures	11261
@NP	them	11297
@NP	the dishes	11307
@NP	the cells	11323
@NP	a hemocytometer	11352
@NP	Cultures cells	11369
@NP	DF-10S	11404
@NP	a final concentration of 100,000 cells/µl	11443
@NP	a final concentration	11443
@NP	100,000 cells/µl	11468
@NP	Samples of the different cultures	11486
@NP	Samples	11486
@NP	the different cultures	11497
@NP	characterization	11538
@NP	Flow-cytometry analysis of OECs .	11575
@NP	Flow-cytometry analysis	11575
@NP	OECs	11602
@NP	cellular preparations	11633
@NP	flow-cytometry analysis	11656
@NP	The cells	11695
@NP	PBS	11722
@NP	trypsin/EDTA in conjunction	11743
@NP	trypsin/EDTA	11743
@NP	conjunction	11759
@NP	the use of a cell scraper	11776
@NP	the use	11776
@NP	a cell scraper	11787
@NP	adherent cells	11812
@NP	cells	11834
@NP	PBS/EDTA	11857
@NP	15 min at 4uC	11892
@NP	15 min	11892
@NP	4uC	11902
@NP	the the anti-p75LNGFr -LRB- 1:100 -RRB- -LRB- Chemicon , Billerica , MA . -RRB-	11912
@NP	the the anti-p75LNGFr -LRB- 1:100 -RRB-	11912
@NP	the the anti-p75LNGFr	11912
@NP	1:100	11935
@NP	Chemicon	11943
@NP	Billerica	11953
@NP	MA .	11964
@NP	.	11968
@NP	the end of the incubation	11973
@NP	the end	11973
@NP	the incubation	11984
@NP	2 ml of PBS/EDTA	12000
@NP	2 ml	12000
@NP	PBS/EDTA	12008
@NP	the cells	12031
@NP	300 g for 5 min	12059
@NP	300 g	12059
@NP	5 min	12069
@NP	Cells	12077
@NP	the secondary antibodies	12103
@NP	phycoerythrin -LRB- 1:200 -RRB-	12144
@NP	phycoerythrin	12144
@NP	1:200	12159
@NP	p75 -LRB- BD Biosciences , San Jose , CA -RRB-	12170
@NP	p75	12170
@NP	BD Biosciences	12175
@NP	San Jose	12191
@NP	CA	12201
@NP	the end of the incubation	12209
@NP	the end	12209
@NP	the incubation	12220
@NP	2 ml of PBS/EDTA	12236
@NP	2 ml	12236
@NP	PBS/EDTA	12244
@NP	the cells	12267
@NP	300 g for 5 min	12295
@NP	300 g	12295
@NP	5 min	12305
@NP	cells	12319
@NP	500 µl of PBS/EDTA	12345
@NP	500 µl	12345
@NP	PBS/EDTA	12355
@NP	The total number of 10,000 events	12365
@NP	The total number	12365
@NP	10,000 events	12385
@NP	a FACSCalibur flowcytometer -LRB- BD Biosciences -RRB-	12415
@NP	a FACSCalibur flowcytometer	12415
@NP	BD Biosciences	12444
@NP	the staining procedure	12475
@NP	Data	12499
@NP	the FACSdiva program -LRB- BD Biosciences -RRB-	12525
@NP	the FACSdiva program	12525
@NP	BD Biosciences	12547
@NP	Proportion of p75 positive cells in the various samples	12564
@NP	Proportion	12564
@NP	p75 positive cells in the various samples	12578
@NP	p75 positive cells	12578
@NP	the various samples	12600
@NP	the fluorescence intensity dot plot	12648
@NP	the total amount of non-labeled cells	12696
@NP	the total amount	12696
@NP	non-labeled cells	12716
@NP	Flow cytometry analysis	12735
@NP	that OB	12782
@NP	primary cultures	12790
@NP	approximately 70 % of p75 positive cells -LRB- Figure 2A -RRB-	12817
@NP	approximately 70 %	12817
@NP	p75 positive cells -LRB- Figure 2A -RRB-	12838
@NP	p75 positive cells	12838
@NP	Figure 2A	12858
@NP	OB purified cultures	12873
@NP	OB	12873
@NP	cultures	12885
@NP	approximately 97 % of p75	12904
@NP	approximately 97 %	12904
@NP	p75	12925
@NP	positive cells	12929
@NP	Figure 2B	12945
@NP	the same time	12968
@NP	OM cultures	12982
@NP	15 % of p75	13010
@NP	15 %	13010
@NP	p75	13017
@NP	positive cells -LRB- Figure 2C -RRB-	13021
@NP	positive cells	13021
@NP	Figure 2C	13037
@NP	OM	13052
@NP	cultures	13064
@NP	approximately 98 % of p75 positive cells -LRB- Figure 2D -RRB-	13083
@NP	approximately 98 %	13083
@NP	p75 positive cells -LRB- Figure 2D -RRB-	13104
@NP	p75 positive cells	13104
@NP	Figure 2D	13124
@NP	GFP labeling of transplanted cells .	13136
@NP	GFP labeling	13136
@NP	transplanted cells	13152
@NP	This evaluation	13172
@NP	6 other rats	13205
@NP	OM group	13231
@NP	3 rats	13241
@NP	each time point -LRB- 30 and 60 days -RRB-	13261
@NP	each time point	13261
@NP	30 and 60 days	13278
@NP	30	13278
@NP	60 days	13285
@NP	five days	13304
@NP	transplantation	13321
@NP	OM-OECs purified cultures were infected with a lentiviral vector harboring	13338
@NP	OM-OECs	13338
@NP	cultures	13355
@NP	a lentiviral vector harboring	13383
@NP	GFP -LRB- multiplicity of infection : 20 , time of exposure overnight -RRB-	13422
@NP	GFP	13422
@NP	multiplicity of infection : 20 , time of exposure overnight	13427
@NP	multiplicity of infection : 20 , time	13427
@NP	multiplicity of infection	13427
@NP	multiplicity	13427
@NP	infection	13443
@NP	20 , time	13454
@NP	20	13454
@NP	time	13458
@NP	exposure overnight	13466
@NP	infection	13502
@NP	80 %	13516
@NP	flow cytometry	13534
@NP	materials and methods	13578
@NP	several washing steps	13609
@NP	GFP positive cells	13632
@NP	Experimental Spinal Cord Lesion and Cell Transplantation Procedure	13685
@NP	experimental groups	13756
@NP	adult Fischer inbred rats -LRB- 225 -- 250 g -RRB-	13777
@NP	adult Fischer inbred rats	13777
@NP	adult Fischer	13777
@NP	225 -- 250 g	13804
@NP	225	13804
@NP	250 g	13808
@NP	All the rats	13826
@NP	intraperitoneal injection	13860
@NP	ketamine hydrochloride	13889
@NP	12.5 mg/kg	13913
@NP	chlorpromazine hydrochloride	13929
@NP	0.625 mg/kg	13959
@NP	Five groups -LRB- n = 10 -RRB-	13973
@NP	Five groups	13973
@NP	n	13986
@NP	10	13989
@NP	Group 1 : Medium group -LRB- Md -RRB-	14021
@NP	Group 1	14021
@NP	Medium group -LRB- Md -RRB-	14030
@NP	Medium group	14030
@NP	Md	14044
@NP	Complete spinal cord transection	14049
@NP	DF-10S	14100
@NP	Group 2 : OB-treated group -LRB- Primary OB -RRB- .	14121
@NP	Group 2	14121
@NP	OB-treated group -LRB- Primary OB -RRB-	14130
@NP	OB-treated group	14130
@NP	Primary OB	14148
@NP	Complete spinal cord transection	14161
@NP	primary olfactory bulb cultures	14212
@NP	Group 3 : OM-treated group -LRB- Primary OM -RRB- .	14263
@NP	Group 3	14263
@NP	OM-treated group -LRB- Primary OM -RRB-	14272
@NP	OM-treated group	14272
@NP	Primary OM	14290
@NP	Complete spinal cord transection	14303
@NP	primary olfactory mucosa cultures	14354
@NP	Group 4 : OB OECs-treated group -LRB- Purified OB -RRB- .	14407
@NP	Group 4	14407
@NP	OB OECs-treated group -LRB- Purified OB -RRB-	14416
@NP	OB OECs-treated group	14416
@NP	OB	14448
@NP	Complete spinal cord transection	14453
@NP	olfactory ensheathing cells	14513
@NP	olfactory bulb	14546
@NP	Group 5 : OM OECs-treated group -LRB- Purified OM -RRB- .	14580
@NP	Group 5	14580
@NP	OM OECs-treated group -LRB- Purified OM -RRB-	14589
@NP	OM OECs-treated group	14589
@NP	OM	14621
@NP	Complete spinal cord transection	14626
@NP	olfactory ensheathing cells	14686
@NP	olfactory mucosa	14719
@NP	Control animals -LRB- Ctrl -RRB-	14755
@NP	Control animals	14755
@NP	Ctrl	14772
@NP	histological analyses	14797
@NP	these no surgery was performed	14824
@NP	these	14824
@NP	no surgery	14830
@NP	all operated groups	14860
@NP	all	14860
@NP	groups	14873
@NP	surgery	14880
@NP	the same operator	14905
@NP	a midline dorsal incision	14942
@NP	a standard bilateral Th10 laminectomy	14969
@NP	great care	15026
@NP	the spinal cord	15060
@NP	The dura	15077
@NP	the level of the Th10 dorsal root	15129
@NP	the level	15129
@NP	the Th10 dorsal root	15142
@NP	the spinal cord	15170
@NP	a microscalpel	15216
@NP	the cord stumps	15232
@NP	a needle	15264
@NP	the two stumps	15292
@NP	completeness of the lesion	15317
@NP	completeness	15317
@NP	the lesion	15333
@NP	spinal cord transection	15363
@NP	cells or medium	15388
@NP	a 5 µl	15428
@NP	Hamilton glass syringe	15435
@NP	a 27 gauge needle	15472
@NP	a micromanipulator	15506
@NP	Md treated animals	15526
@NP	injection of DF-10S	15554
@NP	injection	15554
@NP	DF-10S	15567
@NP	transplanted animals	15579
@NP	cellular preparations	15609
@NP	Medium or cells	15632
@NP	the spinal cord on the site of the lesion	15665
@NP	the spinal cord	15665
@NP	the site of the lesion	15684
@NP	the site	15684
@NP	the lesion	15696
@NP	Injections	15708
@NP	spinal sites	15737
@NP	1.5 mm	15750
@NP	the midline -LRB- 2 sites -RRB- and 2 mm depth : 1 mm	15772
@NP	the midline -LRB- 2 sites -RRB-	15772
@NP	the midline	15772
@NP	2 sites	15785
@NP	2 mm depth : 1 mm	15798
@NP	2 mm depth	15798
@NP	1 mm	15810
@NP	1 mm	15829
@NP	Each animal	15844
@NP	a total	15865
@NP	4 injections	15876
@NP	4x1 µl	15890
@NP	cellular suspension -LRB- 100,000 cells/µl -RRB- or DF-10S	15914
@NP	cellular suspension	15914
@NP	100,000 cells/µl	15935
@NP	DF-10S	15956
@NP	The injection	15964
@NP	0.5 µl / min	15991
@NP	0.5 µl	15991
@NP	min	15999
@NP	The delivery needle	16004
@NP	the injection site for 2 min	16036
@NP	the injection site	16036
@NP	2 min	16059
@NP	reflux	16074
@NP	No immunosuppressant	16082
@NP	All the rats	16113
@NP	heat lamp	16156
@NP	24 hours	16173
@NP	surgery	16188
@NP	antibiotics for the first two weeks -LRB- Ceftriaxone , 80 mg/Kg -RRB-	16205
@NP	antibiotics	16205
@NP	the first two weeks -LRB- Ceftriaxone , 80 mg/Kg -RRB-	16221
@NP	the first two weeks	16221
@NP	Ceftriaxone	16242
@NP	80 mg/Kg	16255
@NP	the experiments	16283
@NP	rats	16300
@NP	standard laboratory food and tap water ad libitum	16318
@NP	standard laboratory food	16318
@NP	tap water ad libitum	16347
@NP	an artificial 12 hours light/dark cycle	16374
@NP	12 hours	16388
@NP	threes	16427
@NP	all the experiments	16442
@NP	the bladder	16462
@NP	every day	16489
@NP	manual abdominal pressure	16502
@NP	rats	16532
@NP	all the precautions	16564
@NP	a high morbidity	16590
@NP	30 %	16633
@NP	10 rats in every group	16656
@NP	10 rats	16656
@NP	every group	16667
@NP	15 rats per group	16679
@NP	15 rats	16679
@NP	group	16691
@NP	95 rats	16712
@NP	this study	16739
@NP	Evaluation Evaluations	16751
@NP	15	16789
@NP	30 and 60 days	16793
@NP	surgery for electrophysiological and behavioral analyses	16814
@NP	surgery	16814
@NP	electrophysiological and behavioral analyses	16826
@NP	60 days	16878
@NP	surgery for histological analysis	16892
@NP	surgery	16892
@NP	histological analysis	16904
@NP	10 rats per group	16929
@NP	10 rats	16929
@NP	group	16941
@NP	GFP	16960
@NP	positive OECs	16964
@NP	30 and 60 days after surgery	16995
@NP	30 and 60 days	16995
@NP	surgery	17016
@NP	6 other rats for Purified OM treated group	17027
@NP	6 other rats	17027
@NP	OM treated group	17053
@NP	Experimental schedule	17071
@NP	Figure 1	17109
@NP	Electrophysiological studies	17119
@NP	Measurement of cord dorsum potentials -LRB- CDP -RRB-	17149
@NP	Measurement of cord dorsum potentials	17149
@NP	Measurement	17149
@NP	cord dorsum potentials	17164
@NP	CDP	17188
@NP	this	17211
@NP	rats	17217
@NP	ketamine hydrochloride -LRB- 30 mg/kg -RRB-	17246
@NP	ketamine hydrochloride	17246
@NP	30 mg/kg	17270
@NP	slight sedation	17299
@NP	an electrode	17322
@NP	the abdomen of the rats for electrical isolation	17366
@NP	the abdomen	17366
@NP	the rats for electrical isolation	17381
@NP	the rats	17381
@NP	electrical isolation	17394
@NP	CDP	17419
@NP	two recording electrodes placed in gastrocnemius muscles separated by 5 mm	17443
@NP	two recording electrodes	17443
@NP	gastrocnemius muscles separated by 5 mm	17478
@NP	gastrocnemius muscles	17478
@NP	5 mm	17513
@NP	spinal cord	17528
@NP	sub-lesional	17563
@NP	the record	17588
@NP	Stimulations	17600
@NP	Th2 level -LRB- above the lesion site -RRB-	17631
@NP	Th2 level	17631
@NP	the lesion site	17648
@NP	a magnetic stimulator -LRB- Magstrim , Rapid 2 ® -RRB-	17671
@NP	a magnetic stimulator	17671
@NP	Magstrim , Rapid 2 ®	17694
@NP	Magstrim	17694
@NP	Rapid 2 ®	17704
@NP	Rapid	17704
@NP	2 ®	17710
@NP	5 stimulations	17717
@NP	30 seconds with an intensity of 90 % for supra maximal response	17745
@NP	30 seconds	17745
@NP	an intensity of 90 % for supra maximal response	17761
@NP	an intensity	17761
@NP	90 % for supra maximal response	17777
@NP	90 %	17777
@NP	supra maximal response	17785
@NP	amplitude	17815
@NP	each animal	17855
@NP	Measurement of locomotor activity .	17868
@NP	Measurement	17868
@NP	locomotor activity	17883
@NP	Measurement of locomotor activity	17903
@NP	Measurement	17903
@NP	locomotor activity	17918
@NP	36 -RSB-	17976
@NP	Animals	17981
@NP	40x40x30 cm compartments	18017
@NP	a lighted and quiet room	18046
@NP	Locomotor activity	18072
@NP	a computerized actimeter	18121
@NP	Versamax , AccuScan Instruments Inc , Ohio , USA	18147
@NP	Versamax	18147
@NP	AccuScan Instruments Inc	18157
@NP	Ohio	18183
@NP	USA	18189
@NP	the horizontal displacements and vertical movements	18211
@NP	the horizontal displacements	18211
@NP	vertical movements	18244
@NP	vertical time and vertical activity	18274
@NP	vertical time	18274
@NP	vertical activity	18292
@NP	The responses	18311
@NP	the total number of beams	18343
@NP	the total number	18343
@NP	beams	18363
@NP	horizontal and vertical activity	18378
@NP	horizontal	18378
@NP	vertical activity	18393
@NP	time	18419
@NP	vertical time	18443
@NP	rats	18461
@NP	six consecutive 10-minutes periods	18473
@NP	CatWalk gait analysis .	18509
@NP	CatWalk	18509
@NP	gait analysis	18517
@NP	CatWalk gait analysis	18532
@NP	37 -RSB-	18592
@NP	the animals	18606
@NP	a horizontal glass runway	18626
@NP	a standard CCD camera	18666
@NP	a computer	18701
@NP	the CatWalk software	18717
@NP	Noldus Information Technology	18739
@NP	Wageningen	18770
@NP	Netherlands	18782
@NP	Animals	18796
@NP	at least three uninterrupted runs per animal	18820
@NP	at least three uninterrupted runs	18820
@NP	animal	18858
@NP	Coordination and different individual paw parameters	18866
@NP	functional recovery	18945
@NP	Histological studies	18966
@NP	All the histological analyses	18988
@NP	the correlation between electrophysiological , locomotor and anatomical recovery	19061
@NP	the correlation	19061
@NP	electrophysiological , locomotor and anatomical recovery	19085
@NP	electrophysiological	19085
@NP	locomotor	19107
@NP	anatomical recovery	19121
@NP	we	19142
@NP	immunostaining	19155
@NP	axonal regrowth , astrocyte reactivity , glial scar and inflammatory response	19174
@NP	axonal regrowth	19174
@NP	astrocyte reactivity	19191
@NP	glial scar	19213
@NP	inflammatory response	19228
@NP	anaesthetized rats	19260
@NP	ice-cold PBS for 2 min and then 4 % paraformaldehyde for 15 min	19319
@NP	ice-cold PBS for 2 min	19319
@NP	ice-cold PBS	19319
@NP	2 min	19336
@NP	4 % paraformaldehyde for 15 min	19351
@NP	4 % paraformaldehyde	19351
@NP	15 min	19375
@NP	Spinal cord segments	19383
@NP	4 % paraformaldehyde for 24 h	19437
@NP	4 % paraformaldehyde	19437
@NP	24 h	19461
@NP	4 °C	19469
@NP	cryopreservation in 30 % sucrose at 4uC	19480
@NP	cryopreservation	19480
@NP	30 % sucrose at 4uC	19500
@NP	30 % sucrose	19500
@NP	4uC	19515
@NP	spinal cord tissue	19520
@NP	longitudinal sections -LRB- 20 µm -RRB- on a cryostat	19552
@NP	longitudinal sections -LRB- 20 µm -RRB-	19552
@NP	longitudinal sections	19552
@NP	20 µm	19575
@NP	a cryostat	19585
@NP	two rinses in PBS	19607
@NP	two rinses	19607
@NP	PBS	19621
@NP	sections on slides	19626
@NP	sections	19626
@NP	slides	19638
@NP	PBS containing 0.2 % Triton X-100 for 30 min	19670
@NP	PBS	19670
@NP	0.2 % Triton X-100 for 30 min	19685
@NP	0.2 % Triton X-100	19685
@NP	30 min	19707
@NP	Sections	19715
@NP	30 min at room temperature	19739
@NP	30 min	19739
@NP	room temperature	19749
@NP	the corresponding primary antibody	19771
@NP	anti-GFAP -LRB- 1/200 , Chemicon , Billerica , MA -RRB-	19807
@NP	anti-GFAP	19807
@NP	1/200	19818
@NP	Chemicon	19825
@NP	Billerica , MA	19835
@NP	anti-neurofilament H -LRB- 1/200 , Chemicon -RRB-	19851
@NP	anti-neurofilament H	19851
@NP	1/200	19873
@NP	Chemicon	19880
@NP	anti-Neurocan -LRB- 1 / 200 , Chemicon -RRB-	19891
@NP	anti-Neurocan	19891
@NP	1	19906
@NP	200 , Chemicon	19909
@NP	200	19909
@NP	Chemicon	19914
@NP	anti-ED1 -LRB- 1/200 , Chemicon -RRB-	19928
@NP	anti-ED1	19928
@NP	1/200	19938
@NP	Chemicon	19945
@NP	the specificity of the staining	19966
@NP	the specificity	19966
@NP	the staining	19985
@NP	positive and negative controls	19999
@NP	the experiments	20054
@NP	addition for each experiment , to measure background	20074
@NP	addition	20074
@NP	each experiment	20087
@NP	background	20115
@NP	slides without primary antibodies	20127
@NP	slides	20127
@NP	primary antibodies	20142
@NP	primary antibody incubation	20182
@NP	sections for ED1 and neurocan stainings	20211
@NP	sections	20211
@NP	ED1 and neurocan stainings	20224
@NP	30 min at room temperature	20266
@NP	30 min	20266
@NP	room temperature	20276
@NP	the PE-conjugated anti-mouse antibody -LRB- 1/500 BD Biosciences -RRB-	20298
@NP	the PE-conjugated anti-mouse antibody	20298
@NP	1/500 BD Biosciences	20337
@NP	1/500	20337
@NP	BD Biosciences	20343
@NP	GFAP and neurofilament antibodies	20360
@NP	Alexa Fluor ® 488	20415
@NP	Images	20433
@NP	a fluorescence microscope	20472
@NP	apotome -LRB- 1006 ; Axioscope ; Zeiss -RRB-	20512
@NP	apotome	20512
@NP	1006	20521
@NP	Axioscope ; Zeiss	20527
@NP	Axioscope	20527
@NP	Zeiss	20538
@NP	immunodensitometry	20552
@NP	areas	20599
@NP	1.410 ^ 6 pixels	20615
@NP	2.15 mm2	20631
@NP	GFAP , neurofilament , neurocan and ED1 stainings	20645
@NP	ImageJ software -LRB- NIH software -RRB-	20699
@NP	ImageJ software	20699
@NP	NIH software	20716
@NP	this	20735
@NP	number of positive pixels	20741
@NP	number	20741
@NP	positive pixels	20751
@NP	the measure tool of ImageJ	20785
@NP	the measure tool	20785
@NP	ImageJ	20805
@NP	the threshold defined with control animals -LRB- without surgery -RRB-	20821
@NP	the threshold	20821
@NP	control animals	20848
@NP	surgery	20873
@NP	Stamegna et al. -LSB- 19 -RSB-	20898
@NP	Stamegna et al. -LSB-	20898
@NP	the localization of transplanted OM-OECs into the spinal cord	20931
@NP	the localization	20931
@NP	transplanted OM-OECs into the spinal cord	20951
@NP	transplanted OM-OECs	20951
@NP	the spinal cord	20977
@NP	GFP-Neurofilament co-staining	20994
@NP	anti GFP antibody -LRB- Santa Cruz Biotechnology , CA -RRB-	21044
@NP	anti GFP antibody	21044
@NP	Santa Cruz Biotechnology	21063
@NP	CA	21089
@NP	Stainings	21094
@NP	MRI	21144
@NP	Experiments	21149
@NP	7 days	21176
@NP	spinal cord transection in 4 other rats for Md , primary OB	21189
@NP	spinal cord transection	21189
@NP	4 other rats for Md , primary OB	21216
@NP	4 other rats	21216
@NP	Md , primary OB	21233
@NP	Md	21233
@NP	primary OB	21237
@NP	OM treated groups -LRB- 140 -- 160 g -RRB-	21261
@NP	OM treated groups	21261
@NP	140 -- 160 g	21280
@NP	140	21280
@NP	160 g	21284
@NP	a 7 Tesla Pharmascan magnet -LRB- Bruker , Germany -RRB-	21294
@NP	a 7 Tesla Pharmascan magnet	21294
@NP	Bruker	21323
@NP	Germany	21331
@NP	anesthetized rats -LRB- 1.5 % isoflurane in O2 / N2O 33 % / 67 % -RRB-	21343
@NP	anesthetized rats	21343
@NP	1.5 % isoflurane in O2 / N2O 33 % / 67 %	21362
@NP	1.5 % isoflurane in O2 / N2O 33 % /	21362
@NP	1.5 % isoflurane	21362
@NP	O2 / N2O 33 % /	21381
@NP	O2	21381
@NP	N2O 33 %	21385
@NP	67 %	21393
@NP	Sagittal T2-weighted images	21399
@NP	relaxation enhancement -LRB- RARE -RRB-	21446
@NP	relaxation enhancement	21446
@NP	RARE	21470
@NP	an accelerating factor	21481
@NP	4	21507
@NP	TR = ≈ 6000 ms	21510
@NP	TR =	21510
@NP	≈ 6000 ms	21514
@NP	TE = 40 ms , slice thickness = 0.5 mm , planar resolution of 100 µm * 100 µm	21524
@NP	TE	21524
@NP	40 ms , slice thickness	21528
@NP	40 ms	21528
@NP	slice thickness	21535
@NP	0.5 mm , planar resolution of 100 µm * 100 µm	21553
@NP	0.5 mm	21553
@NP	planar resolution of 100 µm * 100 µm	21561
@NP	planar resolution	21561
@NP	100 µm	21582
@NP	100 µm	21591
@NP	acquisition time ≈ 35 minutes	21599
@NP	acquisition time	21599
@NP	≈ 35 minutes	21616
@NP	Image analysis	21630
@NP	Image J software	21665
@NP	Statistics Prism software -LRB- Graphpad Software , La Jolla , CA . -RRB-	21683
@NP	Statistics Prism	21683
@NP	software -LRB- Graphpad Software , La Jolla , CA . -RRB-	21700
@NP	software	21700
@NP	Graphpad Software , La Jolla , CA .	21710
@NP	Graphpad Software	21710
@NP	La Jolla	21729
@NP	CA .	21739
@NP	statistics	21757
@NP	All data	21769
@NP	Catwalk analysis	21790
@NP	means	21825
@NP	SEM	21833
@NP	Nonparametric test	21838
@NP	-LRB- Kruskal-Wallis -RRB- , followed by a post test -LRB- Dunns -RRB- ,	21866
@NP	-LRB- Kruskal-Wallis -RRB-	21866
@NP	a post test -LRB- Dunns -RRB-	21896
@NP	a post test	21896
@NP	Dunns	21909
@NP	differences between the groups	21929
@NP	differences	21929
@NP	the groups	21949
@NP	CatWalk analyses	21965
@NP	data	21982
@NP	percentage of runs	22004
@NP	percentage	22004
@NP	runs	22018
@NP	a Fisher 's exact test	22046
@NP	a Fisher 's	22046
@NP	Differences	22083
@NP	statistically significant at * p < 0.05 , ** p < 0.01 , or , and *** p < 0.001	22112
@NP	statistically significant at * p < 0.05 , ** p < 0.01	22112
@NP	statistically significant	22112
@NP	p < 0.05 , ** p	22142
@NP	p	22142
@NP	< 0.05 , ** p	22143
@NP	<	22143
@NP	0.05 , ** p	22144
@NP	0.05	22144
@NP	p	22152
@NP	< 0.01	22153
@NP	<	22153
@NP	0.01	22154
@NP	*** p < 0.001	22168
@NP	*** p <	22168
@NP	*** p	22168
@NP	0.001	22173
@NP	Results Table 1 .	22181
@NP	Results	22181
@NP	Table 1	22189
@NP	Catwalk analysis .	22198
@NP	Catwalk	22198
@NP	analysis	22206
@NP	Figure 1 .	22217
@NP	Figure	22217
@NP	1	22224
@NP	Experimental paradigm	22227
@NP	the timeline of the major experimental manipulations	22262
@NP	the timeline	22262
@NP	the major experimental manipulations	22278
@NP	Cells or medium	22316
@NP	sectioned spinal cords -LRB- D0 -RRB-	22355
@NP	sectioned spinal cords	22355
@NP	D0	22379
@NP	15 , 30 and 60 days after surgery animals	22384
@NP	15	22384
@NP	30 and 60 days after surgery animals	22388
@NP	30 and 60 days	22388
@NP	surgery animals	22409
@NP	electrophysiological and locomotor activities -LRB- D15 , D30 , D60 -RRB-	22443
@NP	electrophysiological and locomotor activities	22443
@NP	D15 , D30 , D60	22490
@NP	Histological analyses	22506
@NP	60 days	22543
@NP	transplantation for all the groups -LRB- D60 -RRB-	22557
@NP	transplantation	22557
@NP	all the groups -LRB- D60 -RRB-	22577
@NP	all the groups	22577
@NP	D60	22593
@NP	n = 10	22599
@NP	n	22599
@NP	= 10	22601
@NP	additional animals of OM-purified OECs	22611
@NP	additional animals	22611
@NP	OM-purified OECs	22633
@NP	tracking of GFP + cells	22650
@NP	tracking	22650
@NP	GFP + cells	22662
@NP	GFP	22662
@NP	cells	22667
@NP	30 and 60	22688
@NP	transplantation	22704
@NP	D30 , D60	22721
@NP	D30	22721
@NP	D60	22726
@NP	Each time point -LRB- n = 3 -RRB- -LRB- in green -RRB- .	22732
@NP	Each time	22732
@NP	point -LRB- n = 3 -RRB- -LRB- in green -RRB-	22742
@NP	point -LRB- n = 3 -RRB-	22742
@NP	point	22742
@NP	n	22749
@NP	3	22753
@NP	Figure 2 .	22769
@NP	Figure	22769
@NP	2	22776
@NP	P75 expression	22779
@NP	primary OB -LRB- A -RRB- and OM -LRB- C -RRB- and purified OB-OECs -LRB- B -RRB-	22797
@NP	primary OB -LRB- A -RRB-	22797
@NP	primary OB	22797
@NP	A	22809
@NP	OM -LRB- C -RRB- and purified OB-OECs -LRB- B -RRB-	22816
@NP	OM -LRB- C -RRB-	22816
@NP	OM	22816
@NP	C	22820
@NP	purified OB-OECs -LRB- B -RRB-	22827
@NP	purified OB-OECs	22827
@NP	B	22845
@NP	OM-OECs -LRB- D -RRB- cultures	22852
@NP	OM-OECs	22852
@NP	D	22861
@NP	cultures	22864
@NP	5 and 10 days in vitro	22880
@NP	5 and 10 days	22880
@NP	cell surface expression of p75 in primary OB and purified OB cultures	22904
@NP	cell surface expression	22904
@NP	p75 in primary OB and purified OB cultures	22931
@NP	p75	22931
@NP	primary OB and purified OB cultures	22938
@NP	primary OB	22938
@NP	purified OB cultures	22953
@NP	flow cytometry	22992
@NP	Primary OB cultures	23008
@NP	p75	23046
@NP	70 % -LRB- A -RRB-	23053
@NP	70 %	23053
@NP	A	23058
@NP	OB purified cultures	23071
@NP	OB	23071
@NP	cultures	23083
@NP	p75	23110
@NP	97 % -LRB- B -RRB-	23117
@NP	97 %	23117
@NP	B	23122
@NP	the same time	23129
@NP	5 and 14 days in vitro cell surface expression of p75	23150
@NP	5 and 14 days	23150
@NP	cell surface expression of p75	23173
@NP	cell surface expression	23173
@NP	p75	23200
@NP	primary OM and purified OM cultures	23222
@NP	primary OM	23222
@NP	purified OM cultures	23237
@NP	flow cytometry	23276
@NP	Primary OM cultures	23292
@NP	p75	23330
@NP	15 % -LRB- C -RRB-	23337
@NP	15 %	23337
@NP	C	23342
@NP	OM purified cultures	23355
@NP	OM	23355
@NP	cultures	23367
@NP	p75	23394
@NP	98 % -LRB- D -RRB-	23401
@NP	98 %	23401
@NP	D	23406
@NP	Numbers	23410
@NP	the total population and the percentage of cells	23427
@NP	the total population	23427
@NP	the percentage of cells	23452
@NP	the percentage	23452
@NP	cells	23470
@NP	the indicated gated region	23487
@NP	Figure 3 .	23516
@NP	Figure	23516
@NP	3	23523
@NP	Analysis of electrophysiological activities .	23526
@NP	Analysis	23526
@NP	electrophysiological activities	23538
@NP	Measurement of cord dorsum potentials -LRB- A -- C -RRB-	23571
@NP	Measurement of cord dorsum potentials	23571
@NP	Measurement	23571
@NP	cord dorsum potentials	23586
@NP	A -- C	23610
@NP	A	23610
@NP	C	23612
@NP	transplantation of OECs	23626
@NP	transplantation	23626
@NP	OECs	23645
@NP	potential amplitude	23668
@NP	all OECs treated groups at all-time points studied	23693
@NP	all OECs	23693
@NP	groups	23710
@NP	all-time points studied	23720
@NP	all-time points	23720
@NP	A -- C	23745
@NP	A	23745
@NP	C	23747
@NP	Md	23751
@NP	Medium , OB	23755
@NP	Medium	23755
@NP	OB	23763
@NP	Olfactory Bulb , OM : Olfactory Mucosa	23767
@NP	Olfactory Bulb	23767
@NP	OM	23783
@NP	Olfactory Mucosa	23787
@NP	Statistical comparisons	23805
@NP	a nonparametric test -LRB- Kruskal-Wallis -RRB-	23850
@NP	a nonparametric test	23850
@NP	Kruskal-Wallis	23872
@NP	Mean6SEM	23889
@NP	data	23909
@NP	10 rats per group	23919
@NP	10 rats	23919
@NP	group	23931
@NP	p value < 0.05	23941
@NP	p value	23941
@NP	0.05	23950
@NP	Figure 4 .	23957
@NP	Figure	23957
@NP	4	23964
@NP	Analysis of locomotor activities .	23967
@NP	Analysis	23967
@NP	locomotor activities	23979
@NP	A -- C : horizontal activity D -- F	24001
@NP	C : horizontal activity D	24003
@NP	C	24003
@NP	horizontal activity D	24006
@NP	vertical activity and G -- I : vertical time	24031
@NP	vertical activity and G	24031
@NP	vertical activity	24031
@NP	G	24053
@NP	I : vertical time	24055
@NP	I	24055
@NP	vertical time	24058
@NP	Measurement of locomotor activity -LRB- A -- C -RRB-	24073
@NP	Measurement of locomotor activity	24073
@NP	Measurement	24073
@NP	locomotor activity	24088
@NP	A -- C	24108
@NP	A	24108
@NP	C	24110
@NP	there	24126
@NP	no significant difference	24135
@NP	the groups for horizontal activity at all-time points	24169
@NP	the groups	24169
@NP	horizontal activity at all-time points	24184
@NP	horizontal activity	24184
@NP	all-time points	24207
@NP	This analyses	24224
@NP	transplantation of Primary OB and Purified OM	24249
@NP	transplantation	24249
@NP	Primary OB	24268
@NP	OM	24292
@NP	vertical activity -LRB- F -RRB- and vertical time -LRB- I -RRB- at 60 days	24303
@NP	vertical activity	24303
@NP	F	24322
@NP	vertical time -LRB- I -RRB- at 60 days	24329
@NP	vertical time -LRB- I -RRB-	24329
@NP	vertical time	24329
@NP	I	24344
@NP	60 days	24350
@NP	Md	24359
@NP	Medium , OB	24363
@NP	Medium	24363
@NP	OB	24371
@NP	Olfactory Bulb , OM : Olfactory Mucosa	24375
@NP	Olfactory Bulb	24375
@NP	OM	24391
@NP	Olfactory Mucosa	24395
@NP	Statistical comparisons	24413
@NP	a nonparametric test -LRB- Kruskal-Wallis -RRB-	24458
@NP	a nonparametric test	24458
@NP	Kruskal-Wallis	24480
@NP	Mean6SEM	24497
@NP	data	24517
@NP	10 rats per group	24527
@NP	10 rats	24527
@NP	group	24539
@NP	p value < 0.05	24549
@NP	p value	24549
@NP	0.05	24557
@NP	Figure 5 .	24564
@NP	Figure	24564
@NP	5	24571
@NP	Histological analyses	24574
@NP	Histological analyses on longitudinal sections	24597
@NP	Histological analyses	24597
@NP	longitudinal sections	24622
@NP	neurofilament -LRB- A -RRB-	24663
@NP	neurofilament	24663
@NP	A	24678
@NP	GFAP -LRB- G -RRB-	24682
@NP	GFAP	24682
@NP	G	24688
@NP	Neurocan -LRB- M -RRB-	24692
@NP	Neurocan	24692
@NP	M	24702
@NP	ED1 -LRB- T -RRB-	24709
@NP	ED1	24709
@NP	T	24714
@NP	These analyses	24718
@NP	Primary OB	24745
@NP	OB	24766
@NP	OM OECs	24782
@NP	axonal regrowth -LRB- neurofilament -RRB- -LRB- A -RRB-	24799
@NP	axonal regrowth -LRB- neurofilament -RRB-	24799
@NP	axonal regrowth	24799
@NP	neurofilament	24816
@NP	A	24832
@NP	astrocyte reactivity -LRB- GFAP -RRB- -LRB- G -RRB-	24843
@NP	astrocyte reactivity -LRB- GFAP -RRB-	24843
@NP	astrocyte reactivity	24843
@NP	GFAP	24865
@NP	G	24872
@NP	glial scar formation -LRB- Neurocan -RRB- -LRB- M -RRB-	24879
@NP	glial scar formation -LRB- Neurocan -RRB-	24879
@NP	glial scar formation	24879
@NP	Neurocan	24901
@NP	M	24912
@NP	the same time	24919
@NP	this analysis	24933
@NP	OECs transplantations	24960
@NP	no influence on monocytes/microglia infiltration -LRB- ED1 -RRB- -LRB- T -RRB-	24986
@NP	no influence	24986
@NP	monocytes/microglia infiltration -LRB- ED1 -RRB- -LRB- T -RRB-	25002
@NP	monocytes/microglia infiltration -LRB- ED1 -RRB-	25002
@NP	monocytes/microglia infiltration	25002
@NP	ED1	25036
@NP	T	25042
@NP	Typical illustrations	25046
@NP	each group	25083
@NP	neurofilament -LRB- B -- F -RRB-	25098
@NP	neurofilament	25098
@NP	B -- F	25113
@NP	B	25113
@NP	F	25115
@NP	GFAP -LRB- H -- L -RRB-	25119
@NP	GFAP	25119
@NP	H -- L	25125
@NP	H	25125
@NP	L	25127
@NP	neurocan -LRB- O -- L -RRB-	25131
@NP	neurocan	25131
@NP	O -- L	25141
@NP	O	25141
@NP	L	25143
@NP	ED1 -LRB- U -- Y -RRB-	25150
@NP	ED1	25150
@NP	U -- Y	25155
@NP	U	25155
@NP	Y	25157
@NP	Md	25161
@NP	Medium , OB	25165
@NP	Medium	25165
@NP	OB	25173
@NP	Olfactory Bulb , OM : Olfactory Mucosa	25177
@NP	Olfactory Bulb	25177
@NP	OM	25193
@NP	Olfactory Mucosa	25197
@NP	Statistical comparisons	25215
@NP	a nonparametric test -LRB- Kruskal - Wallis -RRB-	25260
@NP	a nonparametric test	25260
@NP	Kruskal - Wallis	25282
@NP	Kruskal	25282
@NP	Wallis	25291
@NP	Mean ± SEM	25300
@NP	Mean	25300
@NP	± SEM	25305
@NP	data	25321
@NP	10 rats per group	25331
@NP	10 rats	25331
@NP	group	25343
@NP	p value < 0.05 ; ** : p value < 0.01 and *** : p value < 0.001	25353
@NP	p value	25353
@NP	< 0.05 ; ** : p value < 0.01 and *** : p	25360
@NP	<	25360
@NP	0.05 ; ** : p value	25361
@NP	0.05	25361
@NP	p value	25371
@NP	< 0.01 and *** : p	25378
@NP	<	25378
@NP	0.01 and ***	25379
@NP	p	25393
@NP	< 0.001	25400
@NP	<	25400
@NP	0.001	25401
@NP	Figure 6 .	25409
@NP	Figure	25409
@NP	6	25416
@NP	MRI analyses .	25419
@NP	MRI	25419
@NP	analyses	25423
@NP	MRI analyses	25433
@NP	Primary OB -LRB- C -RRB-	25460
@NP	Primary OB	25460
@NP	C	25472
@NP	OM OECs -LRB- D -RRB-	25488
@NP	OM OECs	25488
@NP	D	25497
@NP	inflammatory infiltrate and edema	25510
@NP	7 days	25544
@NP	transplantation	25557
@NP	Boxes	25574
@NP	areas of injury	25590
@NP	areas	25590
@NP	injury	25599
@NP	Typical illustrations	25607
@NP	control -LRB- A -RRB- , Md -LRB- B -RRB- , Primary OB -LRB- C -RRB-	25643
@NP	control -LRB- A -RRB-	25643
@NP	control	25643
@NP	A	25652
@NP	Md -LRB- B -RRB- , Primary OB -LRB- C -RRB-	25656
@NP	Md	25656
@NP	B	25660
@NP	Primary OB -LRB- C -RRB-	25664
@NP	Primary OB	25664
@NP	C	25676
@NP	OM OECs -LRB- D -RRB-	25692
@NP	OM OECs	25692
@NP	D	25701
@NP	Ctrl : Control , Md : Medium , OB : Olfactory Bulb , OM : Olfactory Mucosa .	25705
@NP	Ctrl	25705
@NP	Control , Md	25711
@NP	Control	25711
@NP	Md	25720
@NP	Medium , OB	25724
@NP	Medium	25724
@NP	OB	25732
@NP	Olfactory Bulb , OM	25736
@NP	Olfactory Bulb	25736
@NP	OM	25752
@NP	Olfactory Mucosa	25756
@NP	Olfactory	25756
@NP	Mucosa	25766
@NP	Illustrations	25774
@NP	four different animals for each group	25810
@NP	four different animals	25810
@NP	each group	25837
@NP	Figure 7 .	25850
@NP	Figure	25850
@NP	7	25857
@NP	GFP + OM-OECs	25872
@NP	GFP	25872
@NP	OM-OECs	25877
@NP	GFP + OM-OECs performed on longitudinal sections	25898
@NP	GFP + OM-OECs	25898
@NP	longitudinal sections	25924
@NP	30 -LRB- A -- C -RRB- and 60 -LRB- D -- F -RRB-	25960
@NP	30 -LRB- A -- C -RRB-	25960
@NP	30	25960
@NP	A -- C	25964
@NP	A	25964
@NP	C	25966
@NP	60 -LRB- D -- F -RRB-	25973
@NP	60	25973
@NP	D -- F	25977
@NP	D	25977
@NP	F	25979
@NP	days	25982
@NP	transplantation	25993
@NP	OECs	26010
@NP	the injury site -LRB- B and E -RRB- and both proximally -LRB- A and D -RRB-	26033
@NP	the injury site	26033
@NP	B and E	26050
@NP	B	26050
@NP	E	26056
@NP	both proximally	26063
@NP	A and D	26080
@NP	A	26080
@NP	D	26086
@NP	C and F	26103
@NP	C	26103
@NP	F	26109
@NP	the injection site	26115
@NP	White arrows	26135
@NP	the lesion site	26158
@NP	GFP/neurofilament co-staining	26175
@NP	OECs	26216
@NP	neurofilament + fibers -LRB- G -- I2 -RRB- , 30 and 60 days	26247
@NP	neurofilament + fibers -LRB- G -- I2 -RRB-	26247
@NP	neurofilament + fibers	26247
@NP	G -- I2	26270
@NP	G	26270
@NP	I2	26272
@NP	30 and 60 days	26277
@NP	surgery	26298
@NP	Scale	26307
@NP	100 µm	26319
@NP	WH = White Matter and GH = Grey	26327
@NP	WH	26327
@NP	= White Matter and GH = Grey	26329
@NP	Illustrations	26366
@NP	three different animals for each time point	26402
@NP	three different animals	26402
@NP	each time point	26430
@NP	Electrophysiological Studies Stimulations	26448
@NP	the lesion site	26511
@NP	CDP	26531
@NP	electrodes placed in gastrocnemius muscles	26555
@NP	electrodes	26555
@NP	gastrocnemius muscles	26576
@NP	These analyses	26599
@NP	D15	26629
@NP	all OECs treated groups	26634
@NP	all OECs	26634
@NP	groups	26651
@NP	a significant improvement of the CDP amplitudes	26668
@NP	a significant improvement	26668
@NP	the CDP amplitudes	26697
@NP	comparison	26719
@NP	the Md group -LRB- p < 0.05 -RRB- -LRB- Figure 3A -RRB-	26733
@NP	the Md group -LRB- p < 0.05 -RRB-	26733
@NP	the Md group	26733
@NP	p < 0.05	26747
@NP	p	26747
@NP	< 0.05	26748
@NP	<	26748
@NP	0.05	26749
@NP	Figure 3A	26756
@NP	Increase of CDP amplitudes	26768
@NP	Increase	26768
@NP	CDP amplitudes	26780
@NP	the full time duration of the experiment	26809
@NP	the full time duration	26809
@NP	the experiment	26835
@NP	all OECs treated groups	26854
@NP	all OECs	26854
@NP	groups	26871
@NP	fact	26882
@NP	all OECs treated groups	26888
@NP	all OECs	26888
@NP	groups	26905
@NP	D30 and D60	26922
@NP	significantly higher CDP amplitudes	26934
@NP	comparison	26973
@NP	the Md group -LRB- p < 0.05 -RRB- -LRB- Figures 3B and C -RRB-	26987
@NP	the Md group -LRB- p < 0.05 -RRB-	26987
@NP	the Md group	26987
@NP	p < 0.05	27001
@NP	p	27001
@NP	< 0.05	27002
@NP	<	27002
@NP	0.05	27003
@NP	Figures 3B and C	27010
@NP	this analysis	27033
@NP	no difference	27047
@NP	the different OECs treated groups -LRB- Figure 3 -RRB-	27087
@NP	the different OECs	27087
@NP	groups -LRB- Figure 3 -RRB-	27114
@NP	groups	27114
@NP	Figure 3	27122
@NP	These results	27133
@NP	transplantations of different types of OECs	27164
@NP	transplantations	27164
@NP	different types of OECs	27184
@NP	different types	27184
@NP	OECs	27203
@NP	electrophysiological recovery	27223
@NP	early -LRB- D15 -RRB- to late time points -LRB- D60 -RRB-	27258
@NP	early -LRB- D15 -RRB-	27258
@NP	late time points -LRB- D60 -RRB-	27273
@NP	late time points	27273
@NP	D60	27291
@NP	Behavioral Studies Measurement of locomotor activity .	27297
@NP	Behavioral Studies	27297
@NP	Measurement of locomotor activity	27316
@NP	Measurement	27316
@NP	locomotor activity	27331
@NP	Measurement of horizontal activity	27351
@NP	Measurement	27351
@NP	horizontal activity	27366
@NP	the full duration of the experiment	27407
@NP	the full duration	27407
@NP	the experiment	27428
@NP	all groups	27443
@NP	no significant difference	27464
@NP	this parameter -LRB- Figures 4A -- C -RRB-	27494
@NP	this parameter	27494
@NP	Figures 4A -- C	27510
@NP	Figures 4A	27510
@NP	C	27521
@NP	These results	27525
@NP	all groups	27556
@NP	the same ability to move and to explore	27572
@NP	D15 and D30	27616
@NP	all the groups	27628
@NP	no significant difference	27650
@NP	vertical activity and vertical time	27680
@NP	vertical activity	27680
@NP	vertical time	27702
@NP	Figures 4D	27717
@NP	Figures	27717
@NP	4D	27725
@NP	E and G -- H	27728
@NP	E and G	27728
@NP	H	27736
@NP	D60 , Primary OB	27752
@NP	OM	27781
@NP	treated groups	27784
@NP	a significant higher vertical activity -LRB- p < 0.05 -RRB-	27809
@NP	a significant higher vertical activity	27809
@NP	p < 0.05	27849
@NP	p	27849
@NP	< 0.05	27850
@NP	<	27850
@NP	0.05	27851
@NP	comparison	27860
@NP	the Md treated group -LRB- Figure 4F -RRB-	27874
@NP	the Md treated group	27874
@NP	Figure 4F	27896
@NP	D60 Primary OB	27922
@NP	OM treated groups	27950
@NP	a significantly higher vertical time -LRB- p < 0.05 -RRB-	27978
@NP	a significantly higher vertical time	27978
@NP	p < 0.05	28016
@NP	p	28016
@NP	< 0.05	28017
@NP	<	28017
@NP	0.05	28018
@NP	comparison	28027
@NP	the Md treated group -LRB- Figure 4I -RRB-	28041
@NP	the Md treated group	28041
@NP	Figure 4I	28063
@NP	These results	28075
@NP	Primary OB	28103
@NP	OM	28127
@NP	locomotor activity	28142
@NP	particular ability to stand up and to maintain a standing position	28165
@NP	a standing position	28212
@NP	later time -LRB- D60 -RRB-	28236
@NP	later time	28236
@NP	D60	28248
@NP	CatWalk gait analysis .	28254
@NP	CatWalk	28254
@NP	gait analysis	28262
@NP	This analysis	28277
@NP	all time points analyzed	28309
@NP	all time points	28309
@NP	there	28334
@NP	no significant differences	28344
@NP	all the groups , due to a high intra-group dispersion -LRB- data not shown -RRB-	28379
@NP	all the groups	28379
@NP	a high intra-group dispersion -LRB- data not shown -RRB-	28402
@NP	a high intra-group dispersion	28402
@NP	data not shown	28433
@NP	data	28433
@NP	contingency analysis	28459
@NP	this	28499
@NP	we	28505
@NP	all the runs	28521
@NP	the animals	28547
@NP	the three distinct periods -LRB- D15 to D60 -RRB-	28566
@NP	the three distinct periods	28566
@NP	D15 to D60	28594
@NP	D15	28594
@NP	D60	28601
@NP	we	28613
@NP	the number	28629
@NP	successes and failures	28643
@NP	the ability of animals	28675
@NP	the ability	28675
@NP	animals	28690
@NP	the corridor	28719
@NP	we	28736
@NP	the ratio of successes and failures	28755
@NP	the ratio	28755
@NP	successes and failures	28768
@NP	each group	28795
@NP	This analysis	28807
@NP	Primary OB , Purified OB and Purified OM treated groups	28833
@NP	Primary OB	28833
@NP	OB	28854
@NP	OM treated groups	28870
@NP	a significantly higher rate of runs	28898
@NP	a significantly higher rate	28898
@NP	runs	28929
@NP	comparison	28945
@NP	the Md treated animals	28959
@NP	0 % of the Md treated group	28991
@NP	0 %	28991
@NP	the Md treated group	28997
@NP	all the runs	29042
@NP	comparison	29059
@NP	21.6 %	29071
@NP	the Primary OB -LRB- p < 0.05 -RRB-	29080
@NP	the Primary OB	29080
@NP	p < 0.05	29096
@NP	p	29096
@NP	< 0.05	29097
@NP	<	29097
@NP	0.05	29098
@NP	26 %	29105
@NP	the Purified OB -LRB- 0.01 < p < 0.001 -RRB-	29112
@NP	the Purified OB	29112
@NP	0.01 < p < 0.001	29129
@NP	0.01 < p	29129
@NP	< 0.001	29135
@NP	<	29135
@NP	0.001	29136
@NP	36.7 %	29147
@NP	the Purified OM	29156
@NP	animals -LRB- p < 0.001 -RRB-	29180
@NP	animals	29180
@NP	p < 0.001	29189
@NP	p	29189
@NP	< 0.001	29190
@NP	<	29190
@NP	0.001	29191
@NP	the corridor	29221
@NP	all the runs -LRB- Table 1 -RRB-	29241
@NP	all the runs	29241
@NP	Table 1	29255
@NP	OM treated group	29284
@NP	a significantly higher probability	29308
@NP	comparison	29354
@NP	the Primary OM treated animals -LRB- p < 0.05 -RRB-	29368
@NP	the Primary OM	29368
@NP	animals -LRB- p < 0.05 -RRB-	29391
@NP	animals	29391
@NP	p < 0.05	29400
@NP	p	29400
@NP	< 0.05	29401
@NP	<	29401
@NP	0.05	29402
@NP	These results	29408
@NP	Primary OB	29439
@NP	OB	29460
@NP	OM treated groups , but not Primary OM treated group	29476
@NP	OM treated groups	29476
@NP	OM	29476
@NP	treated groups	29479
@NP	Primary OM treated group	29503
@NP	Primary OM	29503
@NP	group	29522
@NP	ability	29540
@NP	Histological Analysis All the histological analyses	29557
@NP	Histological Analysis	29557
@NP	All the histological analyses	29579
@NP	longitudinal sections	29627
@NP	D60	29653
@NP	histological analyses on an equivalent area	29658
@NP	histological analyses	29658
@NP	an equivalent area	29683
@NP	Primary OB	29716
@NP	OB	29737
@NP	OM treated groups presented a significantly higher staining for neurofilament	29753
@NP	OM	29753
@NP	treated groups	29756
@NP	a significantly higher staining for neurofilament	29781
@NP	a significantly higher staining	29781
@NP	neurofilament	29817
@NP	a marker of axonal regrowth , in comparison	29840
@NP	a marker	29840
@NP	axonal regrowth	29852
@NP	comparison	29872
@NP	Md treated group -LRB- p < 0.05 -RRB- -LRB- Figure 5A -RRB-	29886
@NP	Md treated group -LRB- p < 0.05 -RRB-	29886
@NP	Md treated group	29886
@NP	p < 0.05	29904
@NP	p	29904
@NP	< 0.05	29905
@NP	<	29905
@NP	0.05	29906
@NP	Figure 5A	29913
@NP	Primary OM treated group	29925
@NP	Primary OM	29925
@NP	group	29944
@NP	difference	29963
@NP	Md treated group -LRB- Figure 5A -RRB-	29979
@NP	Md treated group	29979
@NP	Figure 5A	29997
@NP	Representative pictures	30009
@NP	each group for neurofilament staining -LRB- Figures 5B -- F -RRB-	30051
@NP	each group	30051
@NP	neurofilament staining -LRB- Figures 5B -- F -RRB-	30066
@NP	neurofilament staining	30066
@NP	Figures 5B -- F	30090
@NP	Figures 5B	30090
@NP	F	30101
@NP	similar histological analyses	30117
@NP	all OECs treated groups	30161
@NP	all OECs	30161
@NP	groups	30178
@NP	a significantly lower staining	30195
@NP	GFAP	30230
@NP	a marker of astrocyte reactivity	30244
@NP	a marker	30244
@NP	astrocyte reactivity	30256
@NP	comparison	30281
@NP	Md treated group -LRB- p < 0.05 -RRB- -LRB- Figure 5G -RRB-	30295
@NP	Md treated group -LRB- p < 0.05 -RRB-	30295
@NP	Md treated group	30295
@NP	p < 0.05	30313
@NP	p	30313
@NP	< 0.05	30314
@NP	<	30314
@NP	0.05	30315
@NP	Figure 5G	30322
@NP	38 -RSB-	30334
@NP	Representative pictures	30339
@NP	each group for GFAP staining -LRB- Figures 5H -- L -RRB-	30381
@NP	each group	30381
@NP	GFAP staining -LRB- Figures 5H -- L -RRB-	30396
@NP	GFAP staining	30396
@NP	Figures 5H -- L	30411
@NP	Figures 5H	30411
@NP	L	30422
@NP	We	30426
@NP	neurocan staining , an extracellular matrix -LRB- ECM -RRB- protein	30444
@NP	neurocan staining	30444
@NP	an extracellular matrix -LRB- ECM -RRB- protein	30463
@NP	an extracellular matrix	30463
@NP	ECM	30488
@NP	protein	30493
@NP	the glial scar	30512
@NP	all OECs treated groups	30544
@NP	all OECs	30544
@NP	groups	30561
@NP	a significant reduction	30578
@NP	this staining	30606
@NP	0.01 < p <	30621
@NP	0.01 < p	30621
@NP	0.001 for Primary OM and OB treated groups and p	30628
@NP	0.001	30628
@NP	Primary OM and OB treated groups and p	30638
@NP	Primary OM	30638
@NP	OB treated groups and p	30653
@NP	OB treated groups	30653
@NP	p	30675
@NP	0.001	30677
@NP	OB and OM treated groups	30696
@NP	OB	30696
@NP	OM treated groups	30703
@NP	comparison	30725
@NP	Md treated group -LRB- Figure 5M -RRB-	30739
@NP	Md treated group	30739
@NP	Figure 5M	30757
@NP	interest , Purified OM	30772
@NP	interest	30772
@NP	OM	30791
@NP	treated group	30794
@NP	the greatest reduction of neurocan staining -LRB- p < 0.05 -RRB-	30815
@NP	the greatest reduction	30815
@NP	neurocan staining -LRB- p < 0.05 -RRB-	30841
@NP	neurocan staining	30841
@NP	p < 0.05	30860
@NP	p	30860
@NP	< 0.05	30861
@NP	<	30861
@NP	0.05	30862
@NP	Representative pictures	30869
@NP	each group for neurocan staining -LRB- Figures 5O -- S -RRB-	30911
@NP	each group	30911
@NP	neurocan staining -LRB- Figures 5O -- S -RRB-	30926
@NP	neurocan staining	30926
@NP	Figures 5O -- S	30945
@NP	Figures 5O	30945
@NP	S	30956
@NP	D60	30963
@NP	there	30968
@NP	no difference	30978
@NP	ED1 staining	30995
@NP	a marker of activated microglia , monocytes and macrophages	31017
@NP	a marker	31017
@NP	activated microglia , monocytes and macrophages	31029
@NP	all groups	31085
@NP	fact	31100
@NP	all groups	31106
@NP	a high ED1	31127
@NP	invasion	31139
@NP	the spinal cord parenchyma -LRB- Figure 5T -RRB-	31153
@NP	the spinal cord parenchyma	31153
@NP	Figure 5T	31181
@NP	Representative pictures	31193
@NP	each group for ED1 staining -LRB- Figures 5U -- Y -RRB-	31235
@NP	each group	31235
@NP	ED1 staining -LRB- Figures 5U -- Y -RRB-	31250
@NP	ED1 staining	31250
@NP	Figures 5U -- Y	31264
@NP	Figures 5U	31264
@NP	Y	31275
@NP	Complementary analyses	31278
@NP	order	31319
@NP	the potential presence	31338
@NP	distinct subpopulations of macrophages -LRB- M1 and M2 -RRB-	31364
@NP	distinct subpopulations	31364
@NP	macrophages -LRB- M1 and M2 -RRB-	31391
@NP	macrophages	31391
@NP	M1 and M2	31404
@NP	M1	31404
@NP	M2	31411
@NP	the ED1 + cells	31420
@NP	the ED1	31420
@NP	cells	31429
@NP	this	31440
@NP	histological analyses based on MMP9-ED1 co-staining	31446
@NP	histological analyses	31446
@NP	MMP9-ED1 co-staining	31477
@NP	no difference	31513
@NP	the groups -LRB- data not shown -RRB-	31553
@NP	the groups	31553
@NP	data not shown	31565
@NP	data	31565
@NP	We	31582
@NP	these results	31603
@NP	an in vitro approach	31620
@NP	macrophages -LRB- NR8383 cells -RRB-	31647
@NP	macrophages	31647
@NP	NR8383 cells	31660
@NP	conditioned medium obtained from OM	31688
@NP	conditioned medium	31688
@NP	OM	31721
@NP	-LSB- 7 -RSB-	31736
@NP	Quantification of IL-12 and IL-10 secretion	31741
@NP	Quantification	31741
@NP	IL-12 and IL-10 secretion	31759
@NP	conditioned medium from OM or OB-OECs	31797
@NP	conditioned medium	31797
@NP	OM or OB-OECs	31821
@NP	no effect on macrophage phenotype in culture -LRB- data not shown -RRB-	31839
@NP	no effect	31839
@NP	macrophage phenotype in culture -LRB- data not shown -RRB-	31852
@NP	macrophage phenotype	31852
@NP	culture	31876
@NP	data not shown	31885
@NP	data	31885
@NP	these results	31914
@NP	all OECs treated groups	31945
@NP	all OECs	31945
@NP	groups	31962
@NP	a reduction of GFAP -LRB- astrocyte reactivity -RRB-	31979
@NP	a reduction	31979
@NP	GFAP	31994
@NP	astrocyte reactivity	32000
@NP	neurocan -LRB- glial scar component -RRB-	32026
@NP	neurocan	32026
@NP	glial scar component	32036
@NP	stainings in comparison	32058
@NP	stainings	32058
@NP	comparison	32071
@NP	Md treated group	32085
@NP	particular	32109
@NP	OM treated group	32129
@NP	a significantly greater reduction of neurocan expression in comparison	32156
@NP	a significantly greater reduction	32156
@NP	neurocan expression in comparison	32193
@NP	neurocan expression	32193
@NP	comparison	32216
@NP	all the other OECs treated groups	32230
@NP	all the other OECs	32230
@NP	groups	32257
@NP	it	32273
@NP	Primary OB , Purified OB and Purified OM treated groups	32303
@NP	Primary OB	32303
@NP	OB	32324
@NP	OM treated groups	32340
@NP	Primary OM treated group	32366
@NP	Primary OM	32366
@NP	group	32385
@NP	an increase of the axonal regrowth -LRB- neurofilament -RRB-	32398
@NP	an increase	32398
@NP	the axonal regrowth -LRB- neurofilament -RRB-	32413
@NP	the axonal regrowth	32413
@NP	neurofilament	32434
@NP	comparison	32452
@NP	Md treated group	32466
@NP	MRI Analysis	32484
@NP	the inflammatory infiltrate and formation of the glial scar	32516
@NP	the inflammatory infiltrate and formation	32516
@NP	the glial scar	32561
@NP	early time point	32579
@NP	surgery and/or cellular transplantation	32602
@NP	surgery	32602
@NP	cellular transplantation	32617
@NP	we	32643
@NP	MRI experiments	32656
@NP	7 days	32678
@NP	this analysis 4 other rats of Md , Primary OB and Purified OM	32690
@NP	this analysis 4 other rats of Md	32690
@NP	this analysis	32690
@NP	4 other rats of Md	32704
@NP	4 other rats	32704
@NP	Md	32720
@NP	Primary OB	32724
@NP	OM	32748
@NP	treated groups , which showed higher potential to promote recovery ,	32751
@NP	treated groups	32751
@NP	higher potential to promote recovery	32780
@NP	higher potential	32780
@NP	recovery	32808
@NP	animals -LRB- Figures 6C and D -RRB-	32842
@NP	animals	32842
@NP	Figures 6C and D	32851
@NP	a reduction of the signal intensity -LRB- delimited by white areas -RRB-	32879
@NP	a reduction	32879
@NP	the signal intensity	32894
@NP	white areas	32929
@NP	comparison	32945
@NP	the hyperintense sequences of the Md	32959
@NP	the hyperintense sequences	32959
@NP	the Md	32989
@NP	treated animals -LRB- Figure 6B -RRB-	32996
@NP	treated animals	32996
@NP	Figure 6B	33013
@NP	This result based on T2 * IRM sequences	33025
@NP	This result	33025
@NP	T2 * IRM sequences	33046
@NP	T2	33046
@NP	IRM sequences	33050
@NP	OEC transplantations	33079
@NP	inflammatory infiltrate and edema	33107
@NP	the spinal cord parenchyma at early time	33146
@NP	the spinal cord parenchyma	33146
@NP	early time	33176
@NP	Animals without surgery	33188
@NP	Animals	33188
@NP	surgery	33204
@NP	control -LRB- Figure 6A -RRB-	33222
@NP	control	33222
@NP	Figure 6A	33231
@NP	GFP + OM-OECs	33255
@NP	GFP	33255
@NP	OM-OECs	33260
@NP	this analysis	33272
@NP	6 other rats	33287
@NP	OM treated group , which constituted the most relevant group for clinical use ,	33313
@NP	OM treated group	33313
@NP	the most relevant group for clinical use	33349
@NP	the most relevant group	33349
@NP	clinical use	33377
@NP	GFP + OM-OECs	33414
@NP	GFP	33414
@NP	OM-OECs	33419
@NP	30 and 60 days after surgery	33441
@NP	30 and 60 days	33441
@NP	surgery	33462
@NP	3 rats for each time point	33473
@NP	3 rats	33473
@NP	each time point	33484
@NP	Histological analyses , based on longitudinal sections ,	33501
@NP	Histological analyses	33501
@NP	longitudinal sections	33533
@NP	a similarly high number of GFP + cells	33570
@NP	a similarly high number	33570
@NP	GFP + cells	33597
@NP	GFP	33597
@NP	cells	33602
@NP	the lesion site and both distally -LRB- Figures 7C and F -RRB-	33626
@NP	the lesion site and both distally	33626
@NP	the lesion site and both	33626
@NP	the lesion site	33626
@NP	both	33646
@NP	Figures 7C and F	33661
@NP	Figures 7A and D	33695
@NP	the injection site	33716
@NP	both time points in all the rats transplanted	33738
@NP	both time points	33738
@NP	all the rats transplanted	33758
@NP	all the rats	33758
@NP	Image analysis	33785
@NP	OECs	33818
@NP	a distance of 1.5 cm	33838
@NP	a distance	33838
@NP	1.5 cm	33852
@NP	a maximal distance of the injection sites of around 0.35 cm	33866
@NP	a maximal distance	33866
@NP	the injection sites of around 0.35 cm	33888
@NP	the injection sites	33888
@NP	0.35 cm	33918
@NP	It	33927
@NP	the lesion site	33951
@NP	gap	33980
@NP	60 days	33984
@NP	transplantation -LRB- white arrows -RRB- -LRB- Figure 7E -RRB-	33998
@NP	transplantation -LRB- white arrows -RRB-	33998
@NP	transplantation	33998
@NP	white arrows	34015
@NP	Figure 7E	34030
@NP	contrary	34044
@NP	30 days after transplantation -LRB- Figure 7B -RRB-	34056
@NP	30 days	34056
@NP	transplantation -LRB- Figure 7B -RRB-	34070
@NP	transplantation	34070
@NP	Figure 7B	34087
@NP	the localization of OECs	34110
@NP	the localization	34110
@NP	OECs	34130
@NP	the spinal cord	34140
@NP	GFPNeurofilament co-staining	34157
@NP	OECs	34215
@NP	neurofilament	34247
@NP	30 and 60 days after surgery -LRB- Figures 7G -- I2 -RRB-	34261
@NP	30 and 60 days	34261
@NP	surgery -LRB- Figures 7G -- I2 -RRB-	34282
@NP	surgery	34282
@NP	Figures 7G -- I2	34291
@NP	Figures 7G	34291
@NP	I2	34302
@NP	these results	34319
@NP	OM-OECs	34350
@NP	60 days	34376
@NP	axons	34427
@NP	the lesioned spinal cord	34436
@NP	Discussion Numerous reports	34462
@NP	the role of OECs transplantations	34516
@NP	the role	34516
@NP	OECs transplantations	34528
@NP	SCI using different experimental paradigms -LSB- 13,38 -- 42 -RSB-	34556
@NP	SCI	34556
@NP	different experimental paradigms -LSB- 13,38 -- 42 -RSB-	34566
@NP	different experimental paradigms -LSB- 13,38	34566
@NP	different experimental paradigms	34566
@NP	13,38	34600
@NP	42 -RSB-	34606
@NP	none of these studies	34620
@NP	none	34620
@NP	these studies	34628
@NP	the therapeutic benefit of OM and OB-OECs	34664
@NP	the therapeutic benefit	34664
@NP	OM and OB-OECs	34691
@NP	primary	34712
@NP	cultures	34732
@NP	electrophysiological , functional and histological analyses	34745
@NP	our knowledge	34808
@NP	this	34823
@NP	the first report	34831
@NP	a multi-parametric approach	34867
@NP	the effects of OECs from different sources in a severe SCI model	34895
@NP	the effects	34895
@NP	OECs from different sources in a severe SCI model	34910
@NP	OECs	34910
@NP	different sources in a severe SCI model	34920
@NP	different sources	34920
@NP	a severe SCI model	34941
@NP	our study	34965
@NP	we	34975
@NP	a complete transection model	34990
@NP	the fact	35026
@NP	this model	35040
@NP	a permanent disability	35086
@NP	lesioned animals -LSB- 43,44 -RSB-	35112
@NP	lesioned animals	35112
@NP	43,44 -RSB-	35130
@NP	the completeness and the reproducibility of the section	35151
@NP	the completeness	35151
@NP	the reproducibility of the section	35172
@NP	the reproducibility	35172
@NP	the section	35195
@NP	all the surgeries	35207
@NP	the same operator -LRB- A.M -RRB-	35248
@NP	the same operator	35248
@NP	A.M	35267
@NP	preliminary animals	35276
@NP	we	35320
@NP	immediate electrophysiology analyses	35338
@NP	transection	35381
@NP	the abolition of the electrical signal	35411
@NP	the abolition	35411
@NP	the electrical signal	35428
@NP	Locomotor activity and catwalk tests	35451
@NP	BBB	35523
@NP	functional recovery	35538
@NP	they	35567
@NP	computer-assisted analysis	35576
@NP	quantitative data	35624
@NP	a great precision	35647
@NP	lomomotor activity analyses	35674
@NP	all the lesioned animals	35716
@NP	the same horizontal activity -LRB- ability to move -RRB-	35746
@NP	the same horizontal activity	35746
@NP	ability to move	35776
@NP	ability	35776
@NP	OECs transplantations	35802
@NP	ability in Primary OB	35853
@NP	ability	35853
@NP	Primary OB	35864
@NP	OM treated animals	35888
@NP	OM	35888
@NP	animals	35899
@NP	These results	35908
@NP	Md animals	35933
@NP	Figure	35984
@NP	Our results	35995
@NP	transplantation of OECs	36024
@NP	transplantation	36024
@NP	OECs	36043
@NP	a very promising therapy for SCI independently of their source	36060
@NP	a very promising therapy	36060
@NP	SCI independently of their source	36089
@NP	SCI	36089
@NP	their source	36110
@NP	OECs	36132
@NP	electrophysiological and functional recovery -LRB- Figures 3 and 4 and Table	36145
@NP	electrophysiological	36145
@NP	functional recovery -LRB- Figures 3 and 4 and Table	36170
@NP	functional recovery	36170
@NP	Figures 3 and 4 and Table	36191
@NP	Figures 3 and 4	36191
@NP	Table	36211
@NP	astrocyte reactivity	36229
@NP	glial	36254
@NP	scar -LRB- based on neurocan expression -RRB-	36260
@NP	scar	36260
@NP	neurocan expression	36275
@NP	improved axonal regrowth -LRB- Figure 5 -RRB-	36300
@NP	improved axonal regrowth	36300
@NP	Figure 5	36326
@NP	ED1 staining	36352
@NP	OECs	36379
@NP	no effect	36397
@NP	macrophage / microglia response 60 days after SCI -LRB- Figure 5 -RRB-	36410
@NP	macrophage / microglia response 60 days after SCI	36410
@NP	macrophage	36410
@NP	microglia response 60 days	36422
@NP	microglia response	36422
@NP	60 days	36441
@NP	SCI	36455
@NP	Figure 5	36460
@NP	ability	36490
@NP	processes and formation of the glial scar	36518
@NP	processes and formation	36518
@NP	the glial scar	36545
@NP	early time point	36563
@NP	surgery and/or cellular transplantation	36586
@NP	surgery	36586
@NP	cellular transplantation	36601
@NP	MRI analyses	36626
@NP	Seven days	36655
@NP	surgery	36672
@NP	the MRI sequences in treated groups	36680
@NP	the MRI sequences	36680
@NP	treated groups	36701
@NP	a reduction of the signal intensity	36723
@NP	a reduction	36723
@NP	the signal intensity	36738
@NP	comparison	36762
@NP	the untreated group	36776
@NP	These results	36797
@NP	a reduction of the inflammatory infiltrate and edema	36835
@NP	a reduction	36835
@NP	the inflammatory infiltrate and edema	36850
@NP	a reduction of the cystic cavities	36894
@NP	a reduction	36894
@NP	the cystic cavities	36909
@NP	Both of these hypotheses	36930
@NP	Both	36930
@NP	these hypotheses	36938
@NP	a decrease of the inflammatory processes	36972
@NP	a decrease	36972
@NP	the inflammatory processes	36986
@NP	7 days	37013
@NP	surgery in transplanted groups -LRB- Primary OB and Purified OM groups -RRB-	37026
@NP	surgery	37026
@NP	transplanted groups -LRB- Primary OB and Purified OM groups -RRB-	37037
@NP	transplanted groups	37037
@NP	Primary OB and Purified OM groups	37058
@NP	Primary OB	37058
@NP	OM groups	37082
@NP	Our results	37094
@NP	electric recovery -LRB- based on measurement of cord dorsum potentials -RRB-	37124
@NP	electric recovery	37124
@NP	measurement of cord dorsum potentials	37152
@NP	measurement	37152
@NP	cord dorsum potentials	37167
@NP	transplantation -LRB- D15 -RRB-	37212
@NP	transplantation	37212
@NP	D15	37229
@NP	treated groups	37237
@NP	this recovery	37262
@NP	later functional recovery in primary OB	37291
@NP	later functional recovery	37291
@NP	primary OB	37320
@NP	OM-OECs	37344
@NP	treated groups -LRB- D60 -RRB-	37352
@NP	treated groups	37352
@NP	D60	37368
@NP	These results	37374
@NP	the fact that to induce functional recovery	37419
@NP	the fact	37419
@NP	functional recovery	37443
@NP	neurons	37464
@NP	regrowth	37489
@NP	connections	37515
@NP	neuronal network	37541
@NP	no significant difference about functional recovery	37568
@NP	no significant difference	37568
@NP	functional recovery	37600
@NP	OB-Primary and OM-Purified groups	37642
@NP	our study	37677
@NP	OECs	37703
@NP	OM present the best benefit/risk ratio	37735
@NP	OM present	37735
@NP	the best benefit/risk ratio	37746
@NP	This result	37775
@NP	a fundamental point	37790
@NP	a future human clinical application	37814
@NP	the fact	37858
@NP	OM	37872
@NP	the more accessible source for OECs	37878
@NP	the more accessible source	37878
@NP	OECs	37909
@NP	our study	37918
@NP	purification of primary cultures	37953
@NP	purification	37953
@NP	primary cultures	37969
@NP	no effect	37990
@NP	case of transplantation of OECs obtained from OB -LRB- Figures 3 -- 5 and Table	38003
@NP	case	38003
@NP	transplantation of OECs obtained from OB -LRB- Figures 3 -- 5 and Table	38011
@NP	transplantation	38011
@NP	OECs obtained from OB -LRB- Figures 3 -- 5 and Table	38030
@NP	OECs	38030
@NP	OB -LRB- Figures 3 -- 5 and Table	38049
@NP	OB -LRB- Figures 3	38049
@NP	OB	38049
@NP	Figures 3	38053
@NP	Figures	38053
@NP	3	38061
@NP	5 and Table	38063
@NP	5	38063
@NP	Table	38069
@NP	which	38078
@NP	several ways -LSB- 24 -RSB-	38104
@NP	several ways	38104
@NP	24 -RSB-	38118
@NP	deprivation of microenvironment	38130
@NP	deprivation	38130
@NP	microenvironment	38145
@NP	a loss of the two distinct subpopulations of OECs	38170
@NP	a loss	38170
@NP	the two distinct subpopulations of OECs	38180
@NP	the two distinct subpopulations	38180
@NP	OECs	38215
@NP	primary OB cultures	38231
@NP	a decrease in the recovery of the treated animals -LSB- 21 -RSB-	38263
@NP	a decrease	38263
@NP	the recovery of the treated animals -LSB- 21 -RSB-	38277
@NP	the recovery	38277
@NP	the treated animals -LSB- 21 -RSB-	38293
@NP	the treated animals	38293
@NP	21 -RSB-	38314
@NP	the rate of OECs	38328
@NP	the rate	38328
@NP	OECs	38340
@NP	70 %	38355
@NP	primary OB cultures	38362
@NP	a limiting factor for functional and anatomical recovery in our SCI model	38401
@NP	a limiting factor	38401
@NP	functional and anatomical recovery in our SCI model	38423
@NP	functional and anatomical recovery	38423
@NP	our SCI model	38461
@NP	the `` fibroblast-like '' cells present in primary OB cultures	38485
@NP	the `` fibroblast-like '' cells	38485
@NP	primary OB cultures	38526
@NP	an important role	38555
@NP	the integration of OECs in the spinal cord -LSB- 28,45 -RSB-	38577
@NP	the integration	38577
@NP	OECs in the spinal cord -LSB- 28,45 -RSB-	38596
@NP	OECs	38596
@NP	the spinal cord -LSB- 28,45 -RSB-	38604
@NP	the spinal cord	38604
@NP	28,45 -RSB-	38621
@NP	a recent study	38637
@NP	the main role of fibroblasts on SC	38667
@NP	the main role	38667
@NP	fibroblasts on SC	38684
@NP	fibroblasts	38684
@NP	SC	38699
@NP	axonal regrowth	38706
@NP	Wallerian degeneration in peripheral nerve injury -LRB- PNI -RRB- -LSB- 46 -RSB-	38728
@NP	Wallerian degeneration	38728
@NP	peripheral nerve injury -LRB- PNI -RRB- -LSB- 46 -RSB-	38754
@NP	peripheral nerve injury -LRB- PNI -RRB-	38754
@NP	peripheral nerve injury	38754
@NP	PNI	38779
@NP	46 -RSB-	38785
@NP	It	38790
@NP	the common origin of SC and OECs	38831
@NP	the common origin	38831
@NP	SC and OECs	38852
@NP	`` fibroblast-like '' cells	38870
@NP	the same influence	38901
@NP	OECs	38923
@NP	the case of transplantation	38937
@NP	the case	38937
@NP	transplantation	38949
@NP	a lesioned spinal cord	38968
@NP	14,47 -RSB-	38992
@NP	contrast	39003
@NP	purification of OECs from OM cultures	39013
@NP	purification	39013
@NP	OECs from OM cultures	39029
@NP	OECs	39029
@NP	OM cultures	39039
@NP	both functional and anatomical recoveries	39074
@NP	future clinical applications	39145
@NP	Several hypotheses	39175
@NP	the differences	39208
@NP	primary	39241
@NP	cultures	39262
@NP	transplantation	39276
@NP	primary OM cultures	39300
@NP	a relatively low content	39325
@NP	OECs	39353
@NP	15 %	39359
@NP	the poor functional recovery of this group	39384
@NP	the poor functional recovery	39384
@NP	this group	39416
@NP	several studies	39442
@NP	benefic functional effects	39472
@NP	transplantation of low dose of OECs -LSB- 16,48 -RSB-	39505
@NP	transplantation	39505
@NP	low dose of OECs -LSB- 16,48 -RSB-	39524
@NP	low dose	39524
@NP	OECs -LSB- 16,48 -RSB-	39536
@NP	OECs	39536
@NP	16,48 -RSB-	39542
@NP	Another hypothesis	39550
@NP	cells	39591
@NP	primary OM cultures	39608
@NP	axonal regrowth	39636
@NP	our study	39656
@NP	histological analyses	39667
@NP	Primary OM	39703
@NP	group displayed no difference according to neurofilament staining in comparison	39722
@NP	group	39722
@NP	no difference	39738
@NP	neurofilament staining in comparison	39765
@NP	neurofilament staining	39765
@NP	comparison	39791
@NP	Md group	39805
@NP	the same time Purified OM	39826
@NP	the same time	39826
@NP	OM	39849
@NP	treated group	39852
@NP	a significant increase	39873
@NP	this parameter -LRB- p ,0.05 -RRB- -LRB- Figure 5 -RRB-	39900
@NP	this parameter -LRB- p ,0.05 -RRB-	39900
@NP	this parameter	39900
@NP	p ,0.05	39916
@NP	Figure 5	39925
@NP	We	39936
@NP	transplantation of primary OM cultures after PNI	39969
@NP	transplantation	39969
@NP	primary OM cultures after PNI	39988
@NP	primary OM cultures	39988
@NP	PNI	40014
@NP	functional recovery	40026
@NP	improvement of axonal regrowth -LSB- 23 -RSB-	40054
@NP	improvement	40054
@NP	axonal regrowth -LSB- 23 -RSB-	40069
@NP	axonal regrowth	40069
@NP	23 -RSB-	40086
@NP	The microenvironment present in primary OM cultures	40091
@NP	The microenvironment	40091
@NP	primary OM cultures	40123
@NP	a higher mortality	40161
@NP	cellular transplantation	40186
@NP	One last hypothesis	40212
@NP	the purification method used	40240
@NP	the purification method	40240
@NP	privative medium	40279
@NP	modification or selection of specific cell subpopulations	40310
@NP	modification or selection	40310
@NP	specific cell subpopulations	40339
@NP	A recent study	40369
@NP	primary OM cultures	40402
@NP	distinct populations of cells	40430
@NP	distinct populations	40430
@NP	cells	40454
@NP	OECs , therefore serum deprivation may select specifically one of them -LSB-	40475
@NP	OECs	40475
@NP	serum deprivation may select specifically one of them	40491
@NP	serum deprivation	40491
@NP	one of them	40533
@NP	one	40533
@NP	them	40540
@NP	49 -RSB-	40546
@NP	Complementary studies	40551
@NP	this specific point	40604
@NP	Previous studies	40625
@NP	OM and OB-OECs	40656
@NP	cultures	40688
@NP	PNI	40707
@NP	vivo -LSB- 23,50,51 -RSB-	40714
@NP	vivo	40714
@NP	23,50,51 -RSB-	40720
@NP	They	40731
@NP	some differences such as distinct ability	40747
@NP	some differences	40747
@NP	distinct ability	40772
@NP	axonal regrowth	40799
@NP	ECM	40828
@NP	primary olfactory neurons -LSB- 23,50,51 -RSB-	40853
@NP	primary olfactory neurons	40853
@NP	23,50,51 -RSB-	40880
@NP	our present study	40894
@NP	no major differences	40913
@NP	functional recovery after transplantation of OM and OB-OECs	40937
@NP	functional recovery	40937
@NP	transplantation of OM and OB-OECs	40963
@NP	transplantation	40963
@NP	OM and OB-OECs	40982
@NP	SCI -LRB- Figures 3 -- 5 -RRB-	41016
@NP	SCI	41016
@NP	Figures 3 -- 5	41021
@NP	Figures 3	41021
@NP	5	41031
@NP	our histological analyses	41044
@NP	a significant difference between these groups	41079
@NP	a significant difference	41079
@NP	these groups	41112
@NP	fact	41129
@NP	neurocan staining	41135
@NP	OM group	41174
@NP	a significant reduction of this parameter in comparison	41193
@NP	a significant reduction	41193
@NP	this parameter in comparison	41220
@NP	this parameter	41220
@NP	comparison	41238
@NP	Primary OB	41252
@NP	OB treated groups -LRB- p ,0.05 -RRB- -LRB- Figure 5 -RRB-	41276
@NP	OB treated groups -LRB- p ,0.05 -RRB-	41276
@NP	OB treated groups	41276
@NP	p ,0.05	41295
@NP	Figure 5	41304
@NP	it	41325
@NP	ADAMTS-4	41348
@NP	a major role	41368
@NP	degradation of the glial scar	41384
@NP	degradation	41384
@NP	the glial scar	41399
@NP	chondroitin sulfate proteoglycans -LRB- CSPG -RRB-	41423
@NP	chondroitin sulfate proteoglycans	41423
@NP	CSPG	41458
@NP	a major component of the glial scar with axonal growth inhibitory properties	41468
@NP	a major component	41468
@NP	the glial scar with axonal growth inhibitory properties	41489
@NP	the glial scar	41489
@NP	axonal growth inhibitory properties	41509
@NP	it	41556
@NP	ADAMTS-4	41574
@NP	CSPG as neurocan , brevican and phosphacan	41597
@NP	CSPG	41597
@NP	neurocan , brevican and phosphacan	41605
@NP	vivo	41655
@NP	local administration of ADAMTS-4	41669
@NP	local administration	41669
@NP	ADAMTS-4	41693
@NP	functional recovery	41714
@NP	SCI	41740
@NP	4 -RSB-	41745
@NP	We	41749
@NP	ADAMTS-4	41779
@NP	OM-OECs	41816
@NP	OB-OECs in vitro -LSB- 20 -RSB-	41832
@NP	OB-OECs	41832
@NP	-LSB- 20 -RSB-	41849
@NP	We	41855
@NP	this result	41881
@NP	the protein level -LRB- data not shown -RRB-	41896
@NP	the protein level	41896
@NP	data not shown	41915
@NP	data	41915
@NP	Previous studies	41932
@NP	the ability of OM-OECs	41967
@NP	the ability	41967
@NP	OM-OECs	41982
@NP	the ECM -LSB- 35,52 -RSB-	42002
@NP	the ECM	42002
@NP	35,52 -RSB-	42011
@NP	complementary studies	42030
@NP	the capacity of OM-OECs	42055
@NP	the capacity	42055
@NP	OM-OECs	42071
@NP	particular the potential role of ADAMTS-4 to regulate glial scar	42083
@NP	particular the potential role	42083
@NP	ADAMTS-4	42116
@NP	glial scar	42137
@NP	Visualization of GFP	42170
@NP	Visualization	42170
@NP	GFP	42187
@NP	OM-OECs	42199
@NP	they	42219
@NP	neurofilament + fibers -LRB- Figure 6 -RRB-	42263
@NP	neurofilament + fibers	42263
@NP	Figure 6	42286
@NP	We	42297
@NP	OM-OECs	42312
@NP	the injured spinal cord	42339
@NP	up to 60 days	42379
@NP	OM-OECs , in our model ,	42394
@NP	OM-OECs	42394
@NP	our model	42406
@NP	3.5 mm	42432
@NP	a distance close	42440
@NP	genetically modified SC -LRB- 4.4 mm -RRB-	42480
@NP	genetically modified SC	42480
@NP	4.4 mm	42505
@NP	8 -RSB-	42514
@NP	These results	42518
@NP	the potential of OM-OECs	42542
@NP	the potential	42542
@NP	OM-OECs	42559
@NP	the injured spinal cord	42600
@NP	the accessibility and the recovery properties of OECs	42637
@NP	the accessibility	42637
@NP	the recovery properties of OECs	42659
@NP	the recovery properties	42659
@NP	OECs	42686
@NP	them	42708
@NP	a future relevant biotherapy for spinal cord repair	42716
@NP	a future relevant biotherapy	42716
@NP	spinal cord repair	42749
@NP	Several types of cellular transplantations	42769
@NP	Several types	42769
@NP	cellular transplantations	42786
@NP	SCI recovery	42840
@NP	rodent models	42856
@NP	few of these	42879
@NP	few	42879
@NP	these	42886
@NP	clinical use	42914
@NP	fact for a human application	42931
@NP	fact	42931
@NP	a human application	42940
@NP	the cells	42961
@NP	adult	43017
@NP	weak risk of teratogenicity	43037
@NP	weak risk	43037
@NP	teratogenicity	43050
@NP	functional recovery	43081
@NP	OECs	43102
@NP	all these advantages and criteria	43112
@NP	OM-OECs	43161
@NP	nasal biopsies	43190
@NP	high purity	43223
@NP	a high benefit	43247
@NP	risk balance	43263
@NP	the fact	43283
@NP	OECs	43297
@NP	cells	43321
@NP	long term cultures	43350
@NP	adult primates	43374
@NP	anatomical recoveries -LSB- 29,34	43415
@NP	anatomical recoveries	43415
@NP	29,34	43438
@NP	We	43446
@NP	the potential of different OECs sources	43467
@NP	the potential	43467
@NP	different OECs sources	43484
@NP	a better molecular understanding on the culture effect and subpopulations	43516
@NP	a better molecular understanding	43516
@NP	the culture effect and subpopulations	43552
@NP	the culture effect	43552
@NP	subpopulations	43575
@NP	the clinical potential and use of OECs for SCI	43614
@NP	the clinical potential and use	43614
@NP	OECs for SCI	43648
@NP	OECs	43648
@NP	SCI	43657
@VP	can be proposed to restore lost functions	1222
@VP	be proposed to restore lost functions	1226
@VP	proposed to restore lost functions	1229
@VP	to restore lost functions	1238
@VP	restore lost functions	1241
@VP	have been conducted to induce recovery after SCI	1307
@VP	been conducted to induce recovery after SCI	1312
@VP	conducted to induce recovery after SCI	1317
@VP	to induce recovery after SCI	1327
@VP	induce recovery after SCI	1330
@VP	is based on the use of olfactory ensheathing cells -LRB- OECs -RRB-	1393
@VP	based on the use of olfactory ensheathing cells -LRB- OECs -RRB-	1396
@VP	focusing on OB-OECs although the OM represents a more accessible source of OECs	1680
@VP	represents a more accessible source of OECs	1716
@VP	to induce spinal cord recovery in the same lesion paradigm	1822
@VP	induce spinal cord recovery in the same lesion paradigm	1825
@VP	has never been described	1881
@VP	been described	1891
@VP	described	1896
@VP	purified cultures after a severe model of SCI	2131
@VP	obtained from OB or OM	2228
@VP	induces electrophysiological and functional recovery	2251
@VP	reduces astrocyte reactivity and glial scar formation	2305
@VP	improves axonal regrowth	2363
@VP	is essential for OM-OECs while not required for OB-OECs	2429
@VP	required for OB-OECs	2464
@VP	induced by transplantations of OM-OECs	2659
@VP	to induce recovery	2736
@VP	induce recovery	2739
@VP	can integrate and survive up to 60 days into the spinal cord	2755
@VP	integrate and survive up to 60 days into the spinal cord	2759
@VP	integrate	2759
@VP	survive up to 60 days into the spinal cord	2773
@VP	provide strong support for these cells as a viable therapy for SCI	2840
@VP	is a devastating disease leading to a loss of neural conduction	2947
@VP	leading to a loss of neural conduction	2972
@VP	are interrupted resulting to paraplegia or tetraplegia for patients	3039
@VP	interrupted resulting to paraplegia or tetraplegia for patients	3043
@VP	resulting to paraplegia or tetraplegia for patients	3055
@VP	resulting in a lack of axonal regrowth	3238
@VP	is available for clinical use	3318
@VP	to increase axonal regrowth	3410
@VP	increase axonal regrowth	3413
@VP	to promote functional recovery after SCI using various therapies -LSB- 3,4 -RSB-	3442
@VP	promote functional recovery after SCI using various therapies -LSB- 3,4 -RSB-	3445
@VP	using various therapies -LSB- 3,4 -RSB-	3483
@VP	is used to name all the olfactory ensheathing cells	3700
@VP	used to name all the olfactory ensheathing cells	3703
@VP	to name all the olfactory ensheathing cells	3708
@VP	name all the olfactory ensheathing cells	3711
@VP	to restore both functional and anatomical recoveries after SCI -LSB- 13 -RSB-	3900
@VP	restore both functional and anatomical recoveries after SCI -LSB- 13 -RSB-	3903
@VP	were shown to enhance axonal regrowth	4162
@VP	shown to enhance axonal regrowth	4167
@VP	to enhance axonal regrowth	4173
@VP	enhance axonal regrowth	4176
@VP	regulate astrocyte reactivity , increase angiogenesis	4201
@VP	are constituted of several subpopulations	4369
@VP	constituted of several subpopulations	4373
@VP	is not well described -LSB- 20,21 -RSB-	4489
@VP	well described -LSB- 20,21 -RSB-	4496
@VP	obtained from OM -LRB- OM-OECs -RRB- and OB -LRB- OB-OECs -RRB-	4655
@VP	in vivo -LSB- 22,23 -RSB-	4762
@VP	can greatly influence OECs behaviors in vitro and in vivo -LSB- 21,24 -RSB-	4857
@VP	influence OECs behaviors in vitro and in vivo -LSB- 21,24 -RSB-	4869
@VP	have some relevant consequences	5143
@VP	described by Rubio et al. , after an unilateral bulbectomy	5304
@VP	transplanted either as primary cultures or after additional purification steps	5401
@VP	can alter neurogenic properties of OECs -LSB- 30,31 -RSB-	5526
@VP	alter neurogenic properties of OECs -LSB- 30,31 -RSB-	5530
@VP	induces electrophysiological and functional recovery	5771
@VP	reduces astrocyte reactivity and glial scar formation	5825
@VP	improves axonal regrowth	5883
@VP	providing support for these cells as a new therapy for SCI in human	6006
@VP	used in this study	6144
@VP	is presented in Figure 1	6163
@VP	presented in Figure 1	6166
@VP	cultured in two different ways -LRB- primary and purified -RRB-	6318
@VP	and purified	6358
@VP	purified	6362
@VP	were transplanted after 5 days in vitro -LRB- DIV -RRB-	6431
@VP	transplanted after 5 days in vitro -LRB- DIV -RRB-	6436
@VP	Purified OB	6486
@VP	were transplanted after 10 DIV	6518
@VP	transplanted after 10 DIV	6523
@VP	Purified OM	6558
@VP	were transplanted after 14 DIV	6590
@VP	transplanted after 14 DIV	6595
@VP	were transplanted immediately after spinal cord transection	6647
@VP	transplanted immediately after spinal cord transection	6652
@VP	were performed blindly 60 days after transplantation for all the groups	6850
@VP	performed blindly 60 days after transplantation for all the groups	6855
@VP	treated with Md , Primary OB and Purified OM	6948
@VP	treated with Md , Primary OB	6948
@VP	Purified OM	6980
@VP	showed higher potential to promote recovery	6999
@VP	to promote recovery	7023
@VP	promote recovery	7026
@VP	were used for MRI analyses 7 days after transplantation	7044
@VP	used for MRI analyses 7 days after transplantation	7049
@VP	purified cells	7113
@VP	constituted the most relevant group for clinical use	7135
@VP	were labeled with GFP to visualize them 30 and 60 days after transplantation	7189
@VP	labeled with GFP to visualize them 30 and 60 days after transplantation	7194
@VP	to visualize them 30 and 60 days after transplantation	7211
@VP	visualize them 30 and 60 days after transplantation	7214
@VP	were used -LRB- Charles River , L'Arbresle , France -RRB-	7547
@VP	used -LRB- Charles River , L'Arbresle , France -RRB-	7552
@VP	identified by implantation of glass tag -LRB- Biolog-id , Bernay , France -RRB-	7615
@VP	have been used to perform blindly analyses	7702
@VP	been used to perform blindly analyses	7707
@VP	used to perform blindly analyses	7712
@VP	to perform blindly analyses	7717
@VP	perform blindly analyses	7720
@VP	have been performed in semi-sterile conditions with autoclaved surgery tools	7772
@VP	been performed in semi-sterile conditions with autoclaved surgery tools	7777
@VP	performed in semi-sterile conditions with autoclaved surgery tools	7782
@VP	prepared as described previously with slight modifications -LSB- 25,26 -RSB-	7900
@VP	described previously with slight modifications -LSB- 25,26 -RSB-	7912
@VP	were deeply anesthetized -LRB- isofluorane -RRB- and decapitated	7982
@VP	were deeply anesthetized -LRB- isofluorane -RRB-	7982
@VP	decapitated	8025
@VP	buffered salt solution -LRB- H.B.S.S , Invitrogen , Carlsbad , CA -RRB-	8110
@VP	removing the meninges	8176
@VP	containing 0.1 % trypsin -LRB- Invitrogen -RRB- and OB	8207
@VP	were incubated for 45 min at 37 °C	8251
@VP	incubated for 45 min at 37 °C	8256
@VP	stopped by adding Dulbecco 's Modified Eagle 's	8305
@VP	adding Dulbecco 's Modified Eagle 's	8316
@VP	Modified Eagle 's	8334
@VP	supplemented with 10 % Fetal Bovine Serum -LRB- F.B.S , Invitrogen -RRB-	8395
@VP	centrifugated at 1.000 RPM for 3 min	8525
@VP	resuspended in DF-10S	8563
@VP	centrifugated again	8589
@VP	using a micropipette	8652
@VP	was obtained	8709
@VP	obtained	8713
@VP	plating	8729
@VP	were removed by pipetting	8763
@VP	removed by pipetting	8768
@VP	were incubated at 37 °C , 5 % CO2	8963
@VP	incubated at 37 °C , 5 % CO2	8968
@VP	was changed every two days	9006
@VP	changed every two days	9010
@VP	plating	9050
@VP	were used for transplantation	9079
@VP	used for transplantation	9084
@VP	was opened sagittally with a spatula	9145
@VP	opened sagittally with a spatula	9149
@VP	was cut in small pieces	9189
@VP	cut in small pieces	9193
@VP	was taken to avoid to take cartilage	9219
@VP	taken to avoid to take cartilage	9223
@VP	to avoid to take cartilage	9229
@VP	avoid to take cartilage	9232
@VP	to take cartilage	9238
@VP	take cartilage	9241
@VP	could have been contaminated with respiratory epithelium	9627
@VP	have been contaminated with respiratory epithelium	9633
@VP	been contaminated with respiratory epithelium	9638
@VP	contaminated with respiratory epithelium	9643
@VP	was removed from the dorso-anterior region of the septum	9704
@VP	removed from the dorso-anterior region of the septum	9708
@VP	were cultivated with the same protocol that for OB cultures -LSB- 25 -RSB-	9776
@VP	cultivated with the same protocol that for OB cultures -LSB- 25 -RSB-	9781
@VP	-LSB- 25 -RSB-	9836
@VP	plating	9858
@VP	were used for transplantation	9887
@VP	used for transplantation	9892
@VP	harvested cell types -LSB- 32 -RSB-	10093
@VP	obtained from OB	10280
@VP	resuspended in DF-10S	10301
@VP	seeded on uncoated flask	10324
@VP	cultured at 37 °C with 5 % CO2	10353
@VP	removed and re-plated on other uncoated flasks	10415
@VP	incubated for additional 36 h.	10466
@VP	removed and replated on 25 cm2 poly-L-lysine-coated culture flasks with DF-10S	10537
@VP	removed	10537
@VP	replated on 25 cm2	10549
@VP	plating	10632
@VP	purified cultures	10644
@VP	were used for transplantation	10662
@VP	used for transplantation	10667
@VP	described by Bianco and modified by Gueye et al. -LSB- 34,35 -RSB-	10753
@VP	described by Bianco	10753
@VP	modified by Gueye et al. -LSB-	10777
@VP	split by trypsinisation	10866
@VP	was performed 1 week after	11089
@VP	performed 1 week after	11093
@VP	plating	11137
@VP	purified cultures	11149
@VP	were used for transplantation	11167
@VP	used for transplantation	11172
@VP	were trypsinized to remove them from the dishes	11270
@VP	trypsinized to remove them from the dishes	11275
@VP	to remove them from the dishes	11287
@VP	remove them from the dishes	11290
@VP	were counted using a hemocytometer	11333
@VP	counted using a hemocytometer	11338
@VP	using a hemocytometer	11346
@VP	grafting for a final concentration of 100,000 cells/µl	11430
@VP	were prepared for characterization as described below	11520
@VP	prepared for characterization as described below	11525
@VP	described below	11558
@VP	to characterize cellular preparations	11617
@VP	characterize cellular preparations	11620
@VP	was conducted	11680
@VP	conducted	11684
@VP	washed with PBS	11710
@VP	to remove adherent cells	11802
@VP	remove adherent cells	11805
@VP	washed with PBS/EDTA	11845
@VP	was added	12017
@VP	added	12021
@VP	were centrifuged -LRB- 300 g for 5 min -RRB-	12041
@VP	centrifuged -LRB- 300 g for 5 min -RRB-	12046
@VP	was added	12253
@VP	added	12257
@VP	were centrifuged -LRB- 300 g for 5 min -RRB-	12277
@VP	centrifuged -LRB- 300 g for 5 min -RRB-	12282
@VP	were resuspended in 500 µl of PBS/EDTA	12325
@VP	resuspended in 500 µl of PBS/EDTA	12330
@VP	were processed using the FACSdiva program -LRB- BD Biosciences -RRB-	12504
@VP	processed using the FACSdiva program -LRB- BD Biosciences -RRB-	12509
@VP	using the FACSdiva program -LRB- BD Biosciences -RRB-	12519
@VP	purified cultures	12876
@VP	contained approximately 97 % of p75	12894
@VP	contained approximately 98 % of p75 positive cells -LRB- Figure 2D -RRB-	13073
@VP	was performed in 6 other rats for Purified OM group	13188
@VP	performed in 6 other rats for Purified OM group	13192
@VP	Purified OM group	13222
@VP	were used at each time point -LRB- 30 and 60 days -RRB-	13248
@VP	used at each time point -LRB- 30 and 60 days -RRB-	13253
@VP	purified cultures were infected with a lentiviral vector harboring	13346
@VP	were infected with a lentiviral vector harboring	13364
@VP	infected with a lentiviral vector harboring	13369
@VP	was 80 % determined by flow cytometry	13512
@VP	described in `` materials and methods ''	13563
@VP	were injected as described below	13651
@VP	injected as described below	13656
@VP	described below	13668
@VP	were used	13815
@VP	used	13820
@VP	were classified as follows : Group 1 : Medium group -LRB- Md -RRB-	13993
@VP	follows : Group 1 : Medium group -LRB- Md -RRB-	14012
@VP	follows	14012
@VP	was performed	14082
@VP	performed	14086
@VP	was injected	14107
@VP	injected	14111
@VP	was performed	14194
@VP	performed	14198
@VP	were transplanted	14244
@VP	transplanted	14249
@VP	was performed	14336
@VP	performed	14340
@VP	were transplanted	14388
@VP	transplanted	14393
@VP	Purified OB	14439
@VP	was performed and purified olfactory ensheathing cells from olfactory bulb	14486
@VP	performed and purified olfactory ensheathing cells from olfactory bulb	14490
@VP	were transplanted	14561
@VP	transplanted	14566
@VP	Purified OM	14612
@VP	was performed and purified olfactory ensheathing cells from olfactory mucosa	14659
@VP	performed and purified olfactory ensheathing cells from olfactory mucosa	14663
@VP	were transplanted	14736
@VP	transplanted	14741
@VP	were also used for histological analyses , for these no surgery was performed	14778
@VP	used for histological analyses , for these no surgery was performed	14788
@VP	was performed	14841
@VP	performed	14845
@VP	operated groups	14864
@VP	was performed by the same operator as follow	14888
@VP	performed by the same operator as follow	14892
@VP	follow	14926
@VP	was performed with great care , in order to visualize the spinal cord	15007
@VP	performed with great care , in order to visualize the spinal cord	15011
@VP	to visualize the spinal cord	15047
@VP	visualize the spinal cord	15050
@VP	was opened longitudinally and laterally at the level of the Th10 dorsal root	15086
@VP	opened longitudinally and laterally at the level of the Th10 dorsal root	15090
@VP	opened longitudinally	15090
@VP	laterally at the level of the Th10 dorsal root	15116
@VP	was completely sectioned with a microscalpel	15186
@VP	sectioned with a microscalpel	15201
@VP	were lifted	15248
@VP	lifted	15253
@VP	was passed between the two stumps to ensure completeness of the lesion	15273
@VP	passed between the two stumps to ensure completeness of the lesion	15277
@VP	to ensure completeness of the lesion	15307
@VP	ensure completeness of the lesion	15310
@VP	transplanted using a 5 µl Hamilton glass syringe	15409
@VP	using a 5 µl Hamilton glass syringe	15422
@VP	connected to a 27 gauge needle	15459
@VP	attached to a micromanipulator	15494
@VP	received injection of DF-10S	15545
@VP	received cellular preparations	15600
@VP	were injected to the spinal cord on the site of the lesion	15648
@VP	injected to the spinal cord on the site of the lesion	15653
@VP	contained cellular suspension -LRB- 100,000 cells/µl -RRB- or DF-10S	15904
@VP	was given at 0.5 µl / min	15978
@VP	given at 0.5 µl / min	15982
@VP	was left in the injection site for 2 min to avoid reflux	16024
@VP	left in the injection site for 2 min to avoid reflux	16028
@VP	to avoid reflux	16065
@VP	avoid reflux	16068
@VP	was used	16103
@VP	used	16107
@VP	caged individually under heat lamp during 24 hours after surgery	16131
@VP	give antibiotics for the first two weeks -LRB- Ceftriaxone , 80 mg/Kg -RRB-	16200
@VP	caged by threes	16418
@VP	was compressed every day by manual abdominal pressure	16474
@VP	compressed every day by manual abdominal pressure	16478
@VP	were washed daily	16537
@VP	washed daily	16542
@VP	has been recorded , around 30 % , thereby to obtain 10 rats in every group	16607
@VP	been recorded , around 30 % , thereby to obtain 10 rats in every group	16611
@VP	recorded , around 30 % , thereby to obtain 10 rats in every group	16616
@VP	to obtain 10 rats in every group	16646
@VP	obtain 10 rats in every group	16649
@VP	were operated	16697
@VP	operated	16702
@VP	have been used for this study	16720
@VP	been used for this study	16725
@VP	used for this study	16730
@VP	Tracking of GFP	16948
@VP	Purified OM treated group	17044
@VP	is described in Figure 1	17093
@VP	described in Figure 1	17096
@VP	was recorded	17193
@VP	recorded	17197
@VP	to induce slight sedation	17289
@VP	induce slight sedation	17292
@VP	was placed sub-cutaneaously in the abdomen of the rats for electrical isolation	17335
@VP	placed sub-cutaneaously in the abdomen of the rats for electrical isolation	17339
@VP	using two recording electrodes placed in gastrocnemius muscles separated by 5 mm	17437
@VP	placed in gastrocnemius muscles separated by 5 mm	17468
@VP	separated by 5 mm	17500
@VP	has been stimulated in sub-lesional to validate the record	17540
@VP	been stimulated in sub-lesional to validate the record	17544
@VP	stimulated in sub-lesional to validate the record	17549
@VP	to validate the record	17576
@VP	validate the record	17579
@VP	separated by 30 seconds with an intensity of 90 % for supra maximal response	17732
@VP	was recorded and averaged for each animal	17825
@VP	recorded and averaged for each animal	17829
@VP	was performed as described previously -LSB- 36 -RSB-	17937
@VP	performed as described previously -LSB- 36 -RSB-	17941
@VP	described previously -LSB- 36 -RSB-	17954
@VP	placed individually in 40x40x30 cm compartments , in a lighted and quiet room	17994
@VP	crossed -LRB- horizontal and vertical activity -RRB-	18369
@VP	was performed as described elsewhere -LSB- 37 -RSB-	18554
@VP	performed as described elsewhere -LSB- 37 -RSB-	18558
@VP	described elsewhere -LSB- 37 -RSB-	18571
@VP	were tested for at least three uninterrupted runs per animal	18804
@VP	tested for at least three uninterrupted runs per animal	18809
@VP	were assessed to quantify functional recovery	18919
@VP	assessed to quantify functional recovery	18924
@VP	to quantify functional recovery	18933
@VP	quantify functional recovery	18936
@VP	were performed blindly	19018
@VP	performed blindly	19023
@VP	were collected and post-fixed in 4 % paraformaldehyde for 24 h at 4 °C	19404
@VP	collected and post-fixed in 4 % paraformaldehyde for 24 h at 4 °C	19409
@VP	collected	19409
@VP	post-fixed in 4 % paraformaldehyde for 24 h at 4 °C	19423
@VP	was cut into longitudinal sections -LRB- 20 µm -RRB- on a cryostat	19539
@VP	cut into longitudinal sections -LRB- 20 µm -RRB- on a cryostat	19543
@VP	were permeabilized using PBS containing 0.2 % Triton X-100 for 30 min	19645
@VP	using PBS containing 0.2 % Triton X-100 for 30 min	19664
@VP	containing 0.2 % Triton X-100 for 30 min	19674
@VP	To assess the specificity of the staining	19956
@VP	assess the specificity of the staining	19959
@VP	have been used prior to the experiments	20030
@VP	been used prior to the experiments	20035
@VP	used prior to the experiments	20040
@VP	to measure background	20104
@VP	measure background	20107
@VP	were used	20161
@VP	used	20166
@VP	were conjugated with Alexa Fluor ® 488	20394
@VP	conjugated with Alexa Fluor ® 488	20399
@VP	equipped with apotome -LRB- 1006 ; Axioscope ; Zeiss -RRB-	20498
@VP	using ImageJ software -LRB- NIH software -RRB-	20693
@VP	defined with control animals -LRB- without surgery -RRB-	20835
@VP	described by Stamegna et al. -LSB- 19 -RSB-	20885
@VP	To address the localization of transplanted OM-OECs into the spinal cord	20920
@VP	address the localization of transplanted OM-OECs into the spinal cord	20923
@VP	was performed using anti GFP antibody -LRB- Santa Cruz Biotechnology , CA -RRB-	21024
@VP	performed using anti GFP antibody -LRB- Santa Cruz Biotechnology , CA -RRB-	21028
@VP	using anti GFP antibody -LRB- Santa Cruz Biotechnology , CA -RRB-	21038
@VP	were performed as described previously	21104
@VP	performed as described previously	21109
@VP	described previously	21122
@VP	was performed using Image J software	21645
@VP	performed using Image J software	21649
@VP	using Image J software	21659
@VP	was used for statistics	21744
@VP	used for statistics	21748
@VP	are presented as means ± SEM	21808
@VP	presented as means ± SEM	21812
@VP	± SEM	21831
@VP	followed by a post test -LRB- Dunns -RRB-	21884
@VP	to identify differences between the groups	21917
@VP	identify differences between the groups	21920
@VP	are presented as percentage of runs succeed and failed	21987
@VP	presented as percentage of runs succeed and failed	21991
@VP	succeed and failed	22023
@VP	succeed	22023
@VP	failed	22035
@VP	was performed	22068
@VP	performed	22072
@VP	illustrating the timeline of the major experimental manipulations	22249
@VP	were transplanted into sectioned spinal cords -LRB- D0 -RRB-	22332
@VP	transplanted into sectioned spinal cords -LRB- D0 -RRB-	22337
@VP	were performed 30 and 60 after transplantation -LRB- D30 , D60 -RRB-	22673
@VP	performed 30 and 60 after transplantation -LRB- D30 , D60 -RRB-	22678
@VP	was determined by flow cytometry	22974
@VP	determined by flow cytometry	22978
@VP	purified cultures	23074
@VP	were positive for p75 at 97 % -LRB- B -RRB-	23092
@VP	was determined by flow cytometry	23258
@VP	determined by flow cytometry	23262
@VP	purified cultures	23358
@VP	were positive for p75 at 98 % -LRB- D -RRB-	23376
@VP	treated groups at all-time points studied	23702
@VP	studied	23736
@VP	were performed using a nonparametric test -LRB- Kruskal-Wallis -RRB-	23829
@VP	performed using a nonparametric test -LRB- Kruskal-Wallis -RRB-	23834
@VP	using a nonparametric test -LRB- Kruskal-Wallis -RRB-	23844
@VP	represents data from 10 rats per group	23898
@VP	Purified OM	24283
@VP	were performed using a nonparametric test -LRB- Kruskal-Wallis -RRB-	24437
@VP	performed using a nonparametric test -LRB- Kruskal-Wallis -RRB-	24442
@VP	using a nonparametric test -LRB- Kruskal-Wallis -RRB-	24452
@VP	represents data from 10 rats per group	24506
@VP	Purified OB	24757
@VP	increase axonal regrowth -LRB- neurofilament -RRB- -LRB- A -RRB-	24790
@VP	were performed using a nonparametric test -LRB- Kruskal - Wallis -RRB-	25239
@VP	performed using a nonparametric test -LRB- Kruskal - Wallis -RRB-	25244
@VP	using a nonparametric test -LRB- Kruskal - Wallis -RRB-	25254
@VP	represents data from 10 rats per group	25310
@VP	value < 0.001	25395
@VP	revealed that Primary OB -LRB- C -RRB-	25446
@VP	decreased inflammatory infiltrate and edema 7 days after transplantation	25500
@VP	represent areas of injury	25580
@VP	shown for control -LRB- A -RRB- , Md -LRB- B -RRB- , Primary OB -LRB- C -RRB-	25633
@VP	Purified OM OECs -LRB- D -RRB-	25683
@VP	are representative of four different animals for each group	25788
@VP	Tracking of GFP + OM-OECs	25860
@VP	Tracking of GFP + OM-OECs performed on longitudinal sections	25886
@VP	performed on longitudinal sections	25911
@VP	represent the lesion site	26148
@VP	bar = 100 µm	26313
@VP	= 100 µm	26317
@VP	matter	26358
@VP	are representative of three different animals for each time point	26380
@VP	were performed above the lesion site	26490
@VP	performed above the lesion site	26495
@VP	were measured using electrodes placed in gastrocnemius muscles	26535
@VP	measured using electrodes placed in gastrocnemius muscles	26540
@VP	using electrodes placed in gastrocnemius muscles	26549
@VP	placed in gastrocnemius muscles	26566
@VP	treated groups	26643
@VP	treated groups	26863
@VP	treated groups	26897
@VP	could be observed between the different OECs treated groups -LRB- Figure 3 -RRB-	27061
@VP	be observed between the different OECs treated groups -LRB- Figure 3 -RRB-	27067
@VP	observed between the different OECs treated groups -LRB- Figure 3 -RRB-	27070
@VP	treated groups -LRB- Figure 3 -RRB-	27106
@VP	demonstrate that all groups have the same ability to move and to explore	27539
@VP	have the same ability to move and to explore	27567
@VP	to move and to explore	27589
@VP	to move	27589
@VP	move	27592
@VP	to explore	27601
@VP	explore	27604
@VP	Purified OM treated groups	27941
@VP	Purified OM	28118
@VP	to stand up and to maintain a standing position	28184
@VP	to stand up	28184
@VP	stand up	28187
@VP	to maintain a standing position	28200
@VP	maintain a standing position	28203
@VP	analyzed	28325
@VP	not shown	28438
@VP	was performed	28480
@VP	performed	28484
@VP	based on the ability of animals to have walking into the corridor	28666
@VP	to have walking into the corridor	28698
@VP	have walking into the corridor	28701
@VP	walking into the corridor	28706
@VP	have determined the ratio of successes and failures for each group	28739
@VP	determined the ratio of successes and failures for each group	28744
@VP	Purified OB and Purified OM treated groups	28845
@VP	Purified OB	28845
@VP	Purified OM treated groups	28861
@VP	succeed in comparison to the Md treated animals	28934
@VP	were able to walk into the corridor during all the runs -LRB- Table 1 -RRB-	29198
@VP	to walk into the corridor during all the runs -LRB- Table 1 -RRB-	29208
@VP	walk into the corridor during all the runs -LRB- Table 1 -RRB-	29211
@VP	Purified OM treated group	29275
@VP	to walk in comparison to the Primary OM treated animals -LRB- p < 0.05 -RRB-	29343
@VP	walk in comparison to the Primary OM treated animals -LRB- p < 0.05 -RRB-	29346
@VP	treated animals -LRB- p < 0.05 -RRB-	29383
@VP	Purified OB and Purified OM treated groups , but not Primary OM treated group	29451
@VP	Purified OB	29451
@VP	Purified OM treated groups , but not Primary OM treated group	29467
@VP	treated group	29514
@VP	can improve ability to walk	29528
@VP	improve ability to walk	29532
@VP	to walk	29548
@VP	walk	29551
@VP	were performed on longitudinal sections	29609
@VP	performed on longitudinal sections	29614
@VP	Purified OB	29728
@VP	presented a significantly higher staining for neurofilament	29771
@VP	treated group	29936
@VP	did not show difference with Md treated group -LRB- Figure 5A -RRB-	29950
@VP	show difference with Md treated group -LRB- Figure 5A -RRB-	29958
@VP	presented for each group for neurofilament staining -LRB- Figures 5B -- F -RRB-	30037
@VP	treated groups	30170
@VP	used as a marker of astrocyte reactivity	30236
@VP	are presented for each group for GFAP staining -LRB- Figures 5H -- L -RRB-	30363
@VP	presented for each group for GFAP staining -LRB- Figures 5H -- L -RRB-	30367
@VP	treated groups	30553
@VP	Purified OB and OM treated groups	30687
@VP	Purified OM	30782
@VP	showed the greatest reduction of neurocan staining -LRB- p < 0.05 -RRB-	30808
@VP	are presented for each group for neurocan staining -LRB- Figures 5O -- S -RRB-	30893
@VP	presented for each group for neurocan staining -LRB- Figures 5O -- S -RRB-	30897
@VP	used as a marker of activated microglia , monocytes and macrophages	31009
@VP	presented a high ED1	31117
@VP	invasion into the spinal cord parenchyma -LRB- Figure 5T -RRB-	31139
@VP	are presented for each group for ED1 staining -LRB- Figures 5U -- Y -RRB-	31217
@VP	presented for each group for ED1 staining -LRB- Figures 5U -- Y -RRB-	31221
@VP	were done	31498
@VP	done	31503
@VP	could be observed between the groups -LRB- data not shown -RRB-	31527
@VP	be observed between the groups -LRB- data not shown -RRB-	31533
@VP	observed between the groups -LRB- data not shown -RRB-	31536
@VP	not shown	31570
@VP	cultured with conditioned medium obtained from OM and OB-OECs -LSB- 7 -RSB-	31674
@VP	cultured with conditioned medium obtained from OM	31674
@VP	obtained from OM	31707
@VP	OB-OECs -LSB- 7 -RSB-	31728
@VP	had no effect on macrophage phenotype in culture -LRB- data not shown -RRB-	31835
@VP	not shown	31890
@VP	treated groups	31954
@VP	treated groups	32249
@VP	Purified OB and Purified OM treated groups	32315
@VP	Purified OB	32315
@VP	Purified OM treated groups	32331
@VP	treated group	32377
@VP	performed MRI experiments after 7 days	32646
@VP	Purified OM	32739
@VP	showed higher potential to promote recovery	32773
@VP	to promote recovery	32797
@VP	promote recovery	32800
@VP	were used	32818
@VP	used	32823
@VP	Transplanted animals -LRB- Figures 6C and D -RRB-	32829
@VP	delimited by white areas	32916
@VP	served as control -LRB- Figure 6A -RRB-	33212
@VP	Tracking of GFP + OM-OECs For this analysis	33243
@VP	constituted the most relevant group for clinical use	33337
@VP	were used	33391
@VP	used	33396
@VP	Tracking of GFP + OM-OECs	33402
@VP	was performed 30 and 60 days after surgery on 3 rats for each time point	33427
@VP	performed 30 and 60 days after surgery on 3 rats for each time point	33431
@VP	based on longitudinal sections	33524
@VP	be found at the lesion site and both distally -LRB- Figures 7C and F -RRB-	33614
@VP	found at the lesion site and both distally -LRB- Figures 7C and F -RRB-	33617
@VP	to the injection site at both time points in all the rats transplanted	33713
@VP	transplanted	33771
@VP	To address the localization of OECs into the spinal cord	34099
@VP	address the localization of OECs into the spinal cord	34102
@VP	performed	34190
@VP	shows that OECs were closely associated to neurofilament	34204
@VP	were closely associated to neurofilament	34220
@VP	associated to neurofilament	34233
@VP	demonstrate that OM-OECs can survive up to 60 days	34333
@VP	can survive up to 60 days	34358
@VP	survive up to 60 days	34362
@VP	migrate and are associated with regrowing axons in the lesioned spinal cord	34385
@VP	migrate	34385
@VP	are associated with regrowing axons in the lesioned spinal cord	34397
@VP	associated with regrowing axons in the lesioned spinal cord	34401
@VP	regrowing axons in the lesioned spinal cord	34417
@VP	using different experimental paradigms -LSB- 13,38 -- 42 -RSB-	34560
@VP	compared the therapeutic benefit of OM and OB-OECs , from primary	34655
@VP	is easily reproducible	35051
@VP	induces a permanent disability on lesioned animals -LSB- 43,44 -RSB-	35078
@VP	To ensure of the completeness and the reproducibility of the section	35138
@VP	ensure of the completeness and the reproducibility of the section	35141
@VP	have been performed by the same operator -LRB- A.M -RRB-	35225
@VP	been performed by the same operator -LRB- A.M -RRB-	35230
@VP	performed by the same operator -LRB- A.M -RRB-	35235
@VP	demonstrating the abolition of the electrical signal	35397
@VP	monitor functional recovery , because they are computer-assisted analysis	35530
@VP	are computer-assisted analysis	35572
@VP	allow to collect quantitative data with a great precision	35607
@VP	to collect quantitative data with a great precision	35613
@VP	collect quantitative data with a great precision	35616
@VP	have the same horizontal activity -LRB- ability to move -RRB-	35741
@VP	to move	35784
@VP	move	35787
@VP	induce stand up ability in Primary OB and Purified OM treated animals	35837
@VP	induce stand up ability in Primary OB	35837
@VP	stand up ability in Primary OB	35844
@VP	Purified OM treated animals	35879
@VP	treated animals	35891
@VP	were specifically not able to stand up -LRB- Figure 4 -RRB-	35944
@VP	to stand up -LRB- Figure 4 -RRB-	35971
@VP	to stand up	35971
@VP	stand up	35974
@VP	4	35991
@VP	constitutes a very promising therapy for SCI independently of their source	36048
@VP	reduced	36221
@VP	scar -LRB- based on neurocan expression -RRB-	36260
@VP	based on neurocan expression	36266
@VP	were performed	36639
@VP	performed	36644
@VP	showed a reduction of the signal intensity in comparison to the untreated group	36716
@VP	and Purified OM groups	37069
@VP	based on measurement of cord dorsum potentials	37143
@VP	appeared early after transplantation -LRB- D15 -RRB- in treated groups	37191
@VP	followed by later functional recovery in primary OB	37279
@VP	purified OM-OECs treated groups -LRB- D60 -RRB-	37335
@VP	could be probably explained by the fact that to induce functional recovery	37388
@VP	be probably explained by the fact that to induce functional recovery	37394
@VP	probably explained by the fact that to induce functional recovery	37397
@VP	to induce functional recovery	37433
@VP	induce functional recovery	37436
@VP	to form connections to constitute neuronal network	37507
@VP	form connections to constitute neuronal network	37510
@VP	to constitute neuronal network	37527
@VP	constitute neuronal network	37530
@VP	can be showed between OB-Primary and OM-Purified groups	37620
@VP	be showed between OB-Primary and OM-Purified groups	37624
@VP	showed between OB-Primary and OM-Purified groups	37627
@VP	obtained and purified from OM present the best benefit/risk ratio	37708
@VP	is the more accessible source for OECs	37875
@VP	reported	37943
@VP	obtained from OB -LRB- Figures 3 -- 5 and Table	38035
@VP	can be explained in several ways -LSB- 24 -RSB-	38084
@VP	be explained in several ways -LSB- 24 -RSB-	38088
@VP	explained in several ways -LSB- 24 -RSB-	38091
@VP	leading to a decrease in the recovery of the treated animals -LSB- 21 -RSB-	38252
@VP	be a limiting factor for functional and anatomical recovery in our SCI model	38398
@VP	-LSB- 14,47 -RSB-	38991
@VP	is highly relevant for future clinical applications	39122
@VP	observed between primary and purified cultures upon transplantation	39224
@VP	observed between primary	39224
@VP	purified cultures upon transplantation	39253
@VP	could explain the poor functional recovery of this group	39370
@VP	explain the poor functional recovery of this group	39376
@VP	contaminating cells present in primary OM cultures	39577
@VP	inhibit axonal regrowth	39628
@VP	displayed no difference according to neurofilament staining in comparison	39728
@VP	Purified OM	39840
@VP	could also induce a higher mortality after cellular transplantation	40143
@VP	induce a higher mortality after cellular transplantation	40154
@VP	used	40264
@VP	might induce modification or selection of specific cell subpopulations	40297
@VP	induce modification or selection of specific cell subpopulations	40303
@VP	has reported that primary OM cultures contain distinct populations of cells	40384
@VP	reported that primary OM cultures contain distinct populations of cells	40388
@VP	contain distinct populations of cells	40422
@VP	be OECs , therefore serum deprivation may select specifically one of them -LSB-	40472
@VP	may select specifically one of them	40509
@VP	select specifically one of them	40513
@VP	should be performed to address this specific point	40573
@VP	be performed to address this specific point	40580
@VP	performed to address this specific point	40583
@VP	to address this specific point	40593
@VP	address this specific point	40596
@VP	to induce axonal regrowth	40789
@VP	induce axonal regrowth	40792
@VP	to modulate ECM	40816
@VP	modulate ECM	40819
@VP	to interact with primary olfactory neurons -LSB- 23,50,51 -RSB-	40836
@VP	interact with primary olfactory neurons -LSB- 23,50,51 -RSB-	40839
@VP	were observed upon SCI -LRB- Figures 3 -- 5 -RRB-	40997
@VP	observed upon SCI -LRB- Figures 3 -- 5 -RRB-	41002
@VP	revealed a significant difference between these groups	41070
@VP	presented a significant reduction of this parameter in comparison to Primary OB	41183
@VP	Purified OB treated groups -LRB- p ,0.05 -RRB- -LRB- Figure 5 -RRB-	41267
@VP	could play a major role in degradation of the glial scar	41357
@VP	play a major role in degradation of the glial scar	41363
@VP	are a major component of the glial scar with axonal growth inhibitory properties	41464
@VP	could degrade CSPG as neurocan , brevican and phosphacan in vitro and in vivo	41583
@VP	degrade CSPG as neurocan , brevican and phosphacan in vitro and in vivo	41589
@VP	can promote functional recovery after SCI -LSB- 4 -RSB-	41702
@VP	promote functional recovery after SCI -LSB- 4 -RSB-	41706
@VP	is more highly expressed by OM-OECs than by OB-OECs in vitro -LSB- 20 -RSB-	41788
@VP	expressed by OM-OECs than by OB-OECs in vitro -LSB- 20 -RSB-	41803
@VP	confirmed this result at the protein level -LRB- data not shown -RRB-	41871
@VP	not shown	41920
@VP	have demonstrated the ability of OM-OECs to modulate the ECM -LSB- 35,52 -RSB-	41949
@VP	demonstrated the ability of OM-OECs to modulate the ECM -LSB- 35,52 -RSB-	41954
@VP	to modulate the ECM -LSB- 35,52 -RSB-	41990
@VP	modulate the ECM -LSB- 35,52 -RSB-	41993
@VP	to regulate glial scar	42125
@VP	regulate glial scar	42128
@VP	should be conducted	42149
@VP	be conducted	42156
@VP	conducted	42159
@VP	labeled OM-OECs showed that they were present	42191
@VP	showed that they were present	42207
@VP	were present	42224
@VP	closely associated to neurofilament + fibers -LRB- Figure 6 -RRB-	42241
@VP	could migrate into the injured spinal cord and survive for up to 60 days	42320
@VP	migrate into the injured spinal cord and survive for up to 60 days	42326
@VP	migrate into the injured spinal cord	42326
@VP	survive for up to 60 days	42367
@VP	previously reported genetically modified SC -LRB- 4.4 mm -RRB- -LSB- 8 -RSB-	42460
@VP	to migrate and to integrate into the injured spinal cord	42567
@VP	to migrate	42567
@VP	migrate	42570
@VP	to integrate into the injured spinal cord	42582
@VP	integrate into the injured spinal cord	42585
@VP	allow to propose them as a future relevant biotherapy for spinal cord repair	42691
@VP	to propose them as a future relevant biotherapy for spinal cord repair	42697
@VP	propose them as a future relevant biotherapy for spinal cord repair	42700
@VP	have been tested to promote SCI recovery in rodent models	42812
@VP	been tested to promote SCI recovery in rodent models	42817
@VP	tested to promote SCI recovery in rodent models	42822
@VP	to promote SCI recovery in rodent models	42829
@VP	promote SCI recovery in rodent models	42832
@VP	could be proposed for clinical use	42892
@VP	be proposed for clinical use	42898
@VP	proposed for clinical use	42901
@VP	must be easily sampled and cultured even from adult	42971
@VP	be easily sampled and cultured even from adult	42976
@VP	easily sampled and cultured even from adult	42979
@VP	easily sampled	42979
@VP	cultured even from adult	42998
@VP	must present weak risk of teratogenicity	43024
@VP	present weak risk of teratogenicity	43029
@VP	must induce functional recovery	43069
@VP	induce functional recovery	43074
@VP	have all these advantages and criteria	43107
@VP	be obtained from nasal biopsies and cultured with high purity	43173
@VP	obtained from nasal biopsies and cultured with high purity	43176
@VP	obtained from nasal biopsies	43176
@VP	cultured with high purity	43209
@VP	are differentiated cells	43302
@VP	differentiated cells	43306
@VP	are stable even after long term cultures from adult primates	43328
@VP	induce functional	43393
@VP	have demonstrated the potential of different OECs sources	43449
@VP	demonstrated the potential of different OECs sources	43454
@VP	will further strengthen the clinical potential and use of OECs for SCI	43590
@VP	strengthen the clinical potential and use of OECs for SCI	43603
